American Transplant Congress 2011 Preliminary Program

Saturday, April 30 ........................................................................................................................... 8
Pre-Meeting Symposia – Separate Registration Fee ........................................................................ 8
Updates on Clinical and Technology Advances for the Transplant Scientist (Full Day) ............... 8
Generating B Cell Responses and their Influence on Immune Responses ........................................ 8
Guiding Alloimmune Responses ...................................................................................................... 8
Clinical Update for the Basic Scientist .......................................................................................... 9
New Technologies for Clinical and Basic Scientists ...................................................................... 9
Essential Immunology for the Clinician (Full Day) ........................................................................ 10
  Key Players of the Immune Response ............................................................................................. 10
  Effector Mechanisms of Allograft Injury ........................................................................................ 11
Clinical Applications of Basic Immunology: Part I ......................................................................... 11
Clinical Applications of Basic Immunology: Part II ...................................................................... 12
Transplant Administrative Boot Camp Critical Elements: What Every Team Member Needs to Know (Full Day) .................................................................................................................. 12
  UNOS Regulations and Compliance ............................................................................................ 12
  Quality Improvement Tools ........................................................................................................... 13
  Program Certification Requirements/CMS Rules ............................................................................. 13
  Transplant Center Fiscal Issues and Compliance ............................................................................ 13
  The Troubled Renal Allograft—ARS (Don Hricik) (Half-Day Morning) ......................................... 15
  Predictors of Outcome ................................................................................................................... 15
  Managing the Failing/Failed Renal Allograft .............................................................................. 15
Leading Practices in Organ Donation & Preservation (Half-Day Morning) .................................... 16
  Understanding the Donor Pool, OPO Performance and Organ Utilization .................................... 16
  Emerging Practices to Improve Donation and Transplantation Outcomes .................................... 16
Clinical Trials in Pediatric Solid Organ Transplantation (Half-Day Morning) .................................... 17
  Pediatric Trials: Do We Need Them? How Do We Overcome the Barriers? .................................. 17
  Lessons Learned from Pediatric Trials and Looking to the Future ............................................... 18
Essentials in Transplant Infectious Diseases: An Interactive Case-Based Session (ARS) (Half-Day Afternoon) ....................................................................................................................................... 19
Update on Immunosuppression (Half-Day Afternoon) .................................................................. 20
Critical Care Issues in Liver Transplantation (Half-Day Afternoon) ARS (Levitsky) .................... 21
  “Keeping the Patient Transplantable” ............................................................................................. 21
  Management Dilemmas in the Transplant Recipient ..................................................................... 21
Early Post Operative Complications (Half-Day Afternoon) ............................................................... 22
  Renal Allograft Dysfunction ............................................................................................................. 22
  Liver Allograft Dysfunction ............................................................................................................... 23
ATC 2011 Annual Meeting .............................................................................................................. 25
Opening Reception & Exhibits ........................................................................................................... 25
Poster Session I .................................................................................................................................. 25
Supporter Event .................................................................................................................................. 25
Sunday, May 1 ...................................................................................................................................... 26
Sunrise Symposia .................................................................................................................................. 26
  HIV & Transplantation: What Have We Learned and Where Are We Going? ............................ 26
  CD8 Cells: Suppressors and Effectors .............................................................................................. 26
  Controversies in Transplant Pharmacy Practice ............................................................................. 27
  Deceased Donor Kidney Utilization and the Prospect of Ex-Vivo Repair .................................... 27
Infection and Allograft Survival: “Indirect Effects” ............................................................. 28
Preclinical and Clinical Application of Regulatory T Cells in Transplantation Tolerance .. 28
T Cell Immunity in Clinical Practice .................................................................................... 28
Tolerance in Clinical Transplantation through Mixed Chimerism: Update on Trials? .... 29
The Latest in Extreme Kidney Transplantation—ARS (Dorry Segev) ......................... 29

Early Morning Workshops—Ticketed Event ............................................................................ 30
1. Assessment of Coagulation in End Stage Liver Disease: Pitfalls and Solutions .......... 30
2. Donation after Circulatory Determination of Death (DCDD) in Children: The Ethics, The Process and the Outcomes ................................................................. 30
3. Grant Writing Workshop for Basic Science and Clinical Fellows ............................. 30
4. KDIGO Practice Guidelines in Transplant: How and When Should We Use Them, When Should We Not? ................................................................. 30
5. Surrogate Endpoints in Transplantation ........................................................................ 31
6. The Transplanted Woman: Issues to Consider ............................................................ 31
7. The Current Status of Islet Transplantation ................................................................. 31
8. What Do Animal Models Tell Us About Chronic Rejection? ....................................... 31

Break ......................................................................................................................................... 31

Controversies in Transplantation—ARS (Dorry segev) ....................................................... 31
Geographic Disparities in Liver Transplantation and Novel Approaches for Addressing Them .................................................................................................................... 31

Coffee Break ............................................................................................................................. 32

Midday Symposia ..................................................................................................................... 32
B Lymphocyte/Plasma Cell Homeostasis in Transplantation ........................................... 32
Biomarkers as Diagnostic and Prognostic Tools in Organ Transplantation ...................... 32
New Insights in Fibrogenesis and Tissue Injury ............................................................... 33
Innovative Strategies to Protect the DCD Liver—ARS (Foley) ............................................ 33
Update and Future Directions of New Immunosuppressive Therapies in Renal Transplantation .................................................................................................................... 34
Novel Antivirals in the Pipeline for HCV: Implications for Transplantation ..................... 34
Featured Symposium: Infectious Diseases Update for Pediatric Solid Organ Transplant Recipients ................................................................. 35
Featured Symposium: Xenotransplantation: Lessons for Allotransplantation .................. 36

Break ......................................................................................................................................... 36

Break ......................................................................................................................................... 36

Concurrent Abstract Sessions ................................................................................................... 37
Concurrent Session 1: Acute Rejection ............................................................................. 37
Concurrent Session 2: Allocation and Distribution ............................................................. 37
Concurrent Session 3: Biomarkers and Molecular Markers in Transplantation ............. 37
Concurrent Session 4: Cardiovascular ................................................................................. 37
Concurrent Session 5: Donor Kidney Index, Ischemia Time, Allocation ......................... 37
Concurrent Session 6: Effector Mechanisms of Chronic Rejection ................................. 37
Concurrent Session 7: Infections / Malignancy ................................................................. 37
Concurrent Session 8: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols I ................................................................................................................. 37
Concurrent Session 9: Liver Recurrent Disease, Hepatitis, Liver Transplantation .......................... 37
Concurrent Session 10: Lung Transplant: Pushing the limits .................................................. 37
Concurrent Session 11: Pancreas Transplant: Immunosuppression and Evaluation .................. 37
Concurrent Session 12: Pathological Correlates and Allograft Failure ....................................... 37
Student Program .......................................................................................................................... 37
The Science, the Art and the Allure of Transplantation: An Educational Session Designed for Medical Students and Residents .................................................................................. 37
Fundamental Concepts of Transplantation ............................................................................... 37
Why I Love It ............................................................................................................................. 39
Allied Health Symposium .......................................................................................................... 39
Are We Speaking the Same Language? Transplant Education and Consent ............................. 39
Transplantation in Depth .......................................................................................................... 39
Antibody Mediated Rejection: Pathogenesis, Prevention and Treatment—ARS (Dorry Segev) ................................................................................................................................... 40
Break ......................................................................................................................................... 41
Concurrent Abstract Sessions .................................................................................................... 41
Concurrent Session 13: Acute Cellular Rejection ..................................................................... 41
Concurrent Session 14: Expanding Utilization, Decreasing CIT, Virtual Crossmatch .............. 41
Concurrent Session 15: Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies I ................................................ .......................................................... 41
Concurrent Session 16: Immune Mediated Mechanisms ........................................................... 41
Concurrent Session 17: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols II ........................................................................................................................................ 41
Concurrent Session 18: Outcomes and Complications after Cardiac Transplantation .......... 41
Concurrent Session 19: Pancreas Transplantation: Clinical Management and Complications ..................................................................................................................................... 41
Concurrent Session 20: Surgical / RAS / Retransplant .............................................................. 41
Concurrent Session 21: Therapeutic Approaches and Chronic Rejection ................................. 41
Concurrent Session 22: Tolerance: Clinical Studies .................................................................. 41
Concurrent Session 23: Viruses and Vaccines: In Memory of Mark Pescovitz, MD (1955-2010) .................................................................................................................................. 41
Poster Session II .......................................................................................................................... 41
Industry Event ............................................................................................................................ 41
Monday, May 2 ............................................................................................................................ 43
Sunrise Symposia .......................................................................................................................... 43
Advances in Transplantation for the Diabetic, Uremic Transplant Candidate through Sequential Kidney and Pancreas or Islet Transplantation ................................................................. 43
B Lymphocytes in Transplant Rejection and Tolerance ................................................................ 43
Beyond the SRTR Expected Outcomes: How Should We Determine the Adequacy of Solid Organ Transplant Programs’ Performance?—ARS (Barry Friedman) ........................................................................... 44
Donor-Derived Infections ......................................................................................................... 44
The Emerging Field of Vascularized Composite Allotransplantation ...................................... 45
Hepatitis C Infection after Liver Transplantation—ARS (Seth Karp) ........................................ 45
Long Term Follow Up of the Living Donor: Ethics vs. Finance—ARS (Debbie Hoch) .............. 46
Kidney Paired Donation: National Experience from US, Korea and Australia ...................... 46
Early Morning Workshops—Ticketed Event .............................................................................. 47
9. Diving Into the Deep End of the Liver Donor Pool .......................................................... 47
10. Interpretation of Donor Specific Antibody Testing and Crossmatch Techniques – SOLD OUT ...................................................................................................................................... 47
11. Manuscript Writing Workshop ....................................................................................... 47
12. New Onset Diabetes after Transplantation ..................................................................... 47
13. The Older Transplant Recipient ...................................................................................... 47
14. Transplant Infectious Diseases: Future Directions ......................................................... 47
15. What is the Impact of IL-17 on Transplant Outcomes? .................................................. 47
20. Role of ECMO in Thoracic Transplantation .................................................................. 48

Break......................................................................................................................................... 48
Joint Plenary and Awards ......................................................................................................... 48
State-of-the-Art Address ........................................................................................................... 48
Coffee Break ............................................................................................................................. 48
Midday Symposia ..................................................................................................................... 48
ALDLT: An Update .............................................................................................................. 48
Lymphodepletion and Reconstitution of the T Cell Repertoire ........................................... 49
microRNAs: New Players in Gene Regulation, Tissue Injury and Rejection ...................... 49
Update on “Big Science” in Transplant .............................................................................. 50
Viral Hepatitis in Solid Organ Transplantation ................................................................. 50
Featured Symposium: Improving Long-Term Survival in Thoracic Transplantation: This session is co-sponsored by the International Society for Heart and Lung Transplantation (ISHLT) ................................................................................................................................. 51
Transplant Jeopardy .............................................................................................................. 51
Break......................................................................................................................................... 51
Industry Luncheon .................................................................................................................... 51
Break......................................................................................................................................... 52
Concurrent Abstract Sessions ................................................................................................... 52
Concurrent Session 24: Antigen Presentation / Allorecognition / Dendritic Cells ............... 52
Concurrent Session 25: CNI Toxicity/Transplant Outcomes .............................................. 52
Concurrent Session 26: Donor and Recipient Outcomes .................................................... 52
Concurrent Session 27: Economics, Public Policy ............................................................... 52
Concurrent Session 28: HLA Incompatible Kidney Transplantation ................................ 52
Concurrent Session 29: Immunnoregulation in Transplantation ......................................... 52
Concurrent Session 30: Liver Pediatrics .............................................................................. 52
Concurrent Session 31: Living Liver Donors ....................................................................... 52
Concurrent Session 32: Novel Immunosuppression in Transplantation I ............................ 52
Concurrent Session 33: Obesity and Metabolic Disease ...................................................... 52
Concurrent Session 34: PTLD/Malignancies ....................................................................... 52
Concurrent Session 35: Transplantation Tolerance: Mechanistic Insights ......................... 52
Concurrent Session 36: Xenotransplantation ..................................................................... 52

Transplantation in Depth........................................................................................................... 52
Tolerance is an Active Immunological Process: Part I and Part II ...................................... 52
Part I: Tolerance is an Active Immunological Process: Basic Individual Mechanisms of Tolerance .................................................................................................................. 53
Part II: Tolerance is an Active Immunological Process: Mechanisms of Tolerance in Transplantation and Autoimmunity .............................................................................. 53
Allied Health Symposium ......................................................................................................... 53
Living with an Organ Transplant in 2011: Management of Cardiovascular and Oncologic Co-Morbidity ........................................................................................................................................ 54
Concurrent Abstract Sessions .................................................................................................. 55
Concurrent Session 37: ABO Icompatible Kidney Transplantation ........................................ 55
Concurrent Session 38: Bone Metabolism ........................................................................... 55
Concurrent Session 39: Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies II ........................................................................................................................................ 55
Concurrent Session 40: Host Response to Infection ............................................................. 55
Concurrent Session 41: Islet Cell and Cell Transplantation ................................................... 55
Concurrent Session 42: Kidney Transplantation: Steroid-Free Immunosuppression ............ 55
Concurrent Session 43: Molecular Pathways ....................................................................... 55
Concurrent Session 44: Non-Organ Specific: Allocation ..................................................... 55
Concurrent Session 45: "Omics" in Transplantation ............................................................... 55
Concurrent Session 46: Out with the Old? Novel Immunosuppression in Cardiac Transplantation ............................................................................................................................................... 55
Concurrent Session 47: Small Bowel: All Topics ................................................................ 55
Concurrent Session 48: Surgical and Utilization Issues ......................................................... 55
Poster Session III ...................................................................................................................... 55
AST Business Meeting ............................................................................................................. 55
ATC/ITNS Dinner– Ticketed Event ......................................................................................... 55
Improving Transplant Outcomes: Incorporating Evidence into Transplant Nursing Practice ............................................................................................................................................... 56
Tuesday, May 3 ............................................................................................................................. 57
Sunrise Symposia ...................................................................................................................... 57
The Critically Ill Lung Transplant Candidate: Clinical Management and Donor Selection—ARS (Seth Karp) ............................................................................................................................................... 57
Barriers to the Recovery and Placement of High Risk Organs—ARS (Chris Freise) .......... 57
What Every Clinician Should Know About Designing Better Transplant Trials ................. 58
Development of Small Molecules for Therapeutics ............................................................. 58
Immunosuppressive Agents and Infectious Disease ............................................................. 58
Memory T Cell Responses and Induction of Tolerance ....................................................... 59
The Multi-Disciplinary Approach to Hepatocellular Cancer—ARS (David Foley) ............ 59
Renal Disease in Liver Transplantation—ARS (Seth Karp) ................................................ 60
Early Morning Workshops ........................................................................................................ 60
16. Grant Writing Workshop for Principal Investigators ...................................................... 60
17. Immune Privilege in Transplantation .............................................................................. 61
18. Molecular Reading of Transplant Biopsies ..................................................................... 61
21. The Virtual Crossmatch: Understanding its Role in Wait List Management— SOLD OUT ............................................................................................................................................... 61
22. What Are the Barriers to Optimal Utilization and Outcomes for Kidney Transplantation from Small/Young Pediatric Donors? ............................................................................................................................................... 61
Break ......................................................................................................................................... 61
Joint Plenary and Awards .......................................................................................................... 61
American Transplant Congress 2011 Preliminary Program

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>State-of-the-Art Address</td>
<td>61</td>
</tr>
<tr>
<td>2099 - A Look Back at Tissue Engineering and Regenerative Medicine in the 21st Century</td>
<td>61</td>
</tr>
<tr>
<td>Break</td>
<td>61</td>
</tr>
<tr>
<td>Presidential Addresses</td>
<td>61</td>
</tr>
<tr>
<td>AST and ASTS Awards</td>
<td>62</td>
</tr>
<tr>
<td>Industry Luncheon</td>
<td>62</td>
</tr>
<tr>
<td>Break</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Abstract Sessions</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 50: B Cell / Antibody</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 51: Disparities in Access to Transplantation</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 52: Glomerular Disease / PKD</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 53: Key Topics in Transplant ID</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 54: Kidney Immunosuppression: Induction Therapy I</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 55: Kidney: Pediatrics</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 56: Liver Complications: Surgical Considerations</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 57: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation I</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 58: Novel Aspects in T Regulatory Cell Biology</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 59: Selection Issues</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 60: Therapy of Antibody Mediated Rejection</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 61: Transplantation Monitoring-Beyond Regulation</td>
<td>62</td>
</tr>
<tr>
<td>Concurrent Session 62: Vascularized Composite Allografts - Clinical and Basic Science</td>
<td>62</td>
</tr>
<tr>
<td>FDA Symposium</td>
<td>63</td>
</tr>
<tr>
<td>FDA and Solid Organ Transplantation: Issues in the Practice of Medicine</td>
<td>63</td>
</tr>
<tr>
<td>Allied Health Symposium</td>
<td>63</td>
</tr>
<tr>
<td>Psychosocial Impact on Postoperative Transplant Outcomes</td>
<td>63</td>
</tr>
<tr>
<td>Concurrent Abstract Sessions</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 63: Antibodies / Serologic Assays and Clinical Implications</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 64: DGF / AKI</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 65: Disparities in Outcomes in Transplantation</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 66: Histocompatibility: B Cells and Plasma Cells</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 67: Immunosuppression Preclinical Studies</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 68: Islet: Clinical</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 69: Kidney Immunosuppression: Induction Therapy II</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 70: Kidney: Polyoma</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 71: Liver Complications: Issues that Relate to Surgical and Medical Management</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 72: Liver: Immunosuppression Acute / Chronic Rejection</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 73: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation II</td>
<td>64</td>
</tr>
<tr>
<td>Concurrent Session 74: Novel Mechanisms</td>
<td>64</td>
</tr>
<tr>
<td>Poster Session IV</td>
<td>64</td>
</tr>
<tr>
<td>Career Development Workshop</td>
<td>65</td>
</tr>
<tr>
<td>Early Career Development Symposium</td>
<td>65</td>
</tr>
<tr>
<td>ASTS Business Meeting</td>
<td>66</td>
</tr>
<tr>
<td>Industry Event</td>
<td>66</td>
</tr>
<tr>
<td>ATC NIGHT OUT</td>
<td>66</td>
</tr>
</tbody>
</table>
Wednesday, May 4........................................................................................................................................ 67
Sunrise Symposia........................................................................................................................................ 67
  Role of Mechanical Circulatory Support in Heart Transplantation....................................................... 67
  Assessing the Risk for Kidney Allograft Failure .................................................................................. 67
  Bone Disease in Kidney Transplant Patients: What Diagnostic and Therapeutic Approaches Should We Use?—ARS (Michelle Josephson) ................................................................. 68
  Donor Management: Organ Donation and Critical Care .................................................................. 68
  Small Bowel Transplantation: The Basics—ARS (Deb Sudan).............................................................. 69
  Stem Cell Mediated Therapy in Transplantation .............................................................................. 69
Early Morning Workshops – Ticketed Event .......................................................................................... 69
  23. Challenges in Organ Donor Management .................................................................................. 69
  24. Evolving Role of NK Cells in Solid Organ Transplantation ....................................................... 70
  25. Molecular Expression Profiling to Assess Rejection Risk in Heart Transplantation ............. 70
  26. Risks and Solutions in Transplantation and Policy Implications ............................................ 70
  27. The Current Status of Liver Assist Devices ................................................................................ 70
  28. Vascularized Composite Allotransplantation: Development of Donation Best Practices and Establishment of a VCA Program .................................................................................... 70
  29. WHCOP Advisory Network ....................................................................................................... 70
  30. Auto Islet Transplantation ......................................................................................................... 71
Break....................................................................................................................................................... 71
Joint Plenary and Awards .................................................................................................................... 71
  Keynote Address ............................................................................................................................. 71
  The Not-So Distant Future of Organ Transplantation—Ethical Obstacles and Opportunities .......... 71
Coffee Break ........................................................................................................................................ 71
Concurrent Abstract Sessions .............................................................................................................. 72
  Concurrent Session 75: Antibodies .................................................................................................. 72
  Concurrent Session 76: Antibody-Mediated Rejection: Histologic Findings and Clinical Implications ......................................................................................................................... 72
  Concurrent Session 77: Basic Science: Innate Immunity; Chemokines, Cytokines ..................... 72
  Concurrent Session 78: Complications following Liver Transplantation ..................................... 72
  Concurrent Session 79: Donor Topics ............................................................................................. 72
  Concurrent Session 80: Extended Donor Issues ............................................................................ 72
  Concurrent Session 81: Late Allograft Failure: Immunity and Inflammation .................................. 72
  Concurrent Session 82: Pregnancy and Other Posttransplant Issues ............................................ 72
  Concurrent Session 83: Stem Cell and BMT .................................................................................. 72
What’s Hot, What’s New ..................................................................................................................... 72
Saturday, April 30

PRE-MEETING SYMPOSIA – SEPARATE REGISTRATION FEE

Updates on Clinical and Technology Advances for the Transplant Scientist (Full Day)

Generating B Cell Responses and their Influence on Immune Responses

Moderators: Olivia Martinez, PhD, Stanford University School of Medicine, Stanford, CA and Robert Fairchild, PhD, Cleveland Clinic Foundation, Cleveland, OH

8:00 am – 8:30 am   Development and Function of Follicular Helper T Cells
                 Michael McHeyzer-Williams, PhD
                 Scripps Research Institute
                 La Jolla, CA

8:30 am – 9:00 am   Update on Plasma Cell Function
                 Mark Jay Shlomchik, MD, PhD
                 Yale University
                 New Haven, CT

9:00 am – 9:30 am   Therapies Directed at Attenuating B Cells in the Alloimmune Response
                 Mark Stegall, MD
                 Mayo Clinic
                 Rochester, MN

9:30 am – 10:00 am  Effector and Regulatory B Cell
                 Michael Cancro, PhD
                 University of Pennsylvania
                 Philadelphia, PA

10:00 am – 10:30 am  Break

Guiding Alloimmune Responses

Moderators: Nader Najafian, MD, Brigham & Women’s Hospital, Boston, MA and Peter Heeger, MD, Mt. Sinai School of Medicine, New York, NY

10:30 am – 11:00 am   Novel Insights into Molecular Functions of Natural and Adaptive T Regs
                 Ethan Shevach, MD
American Transplant Congress 2011 Preliminary Program

National Institute of Allergy and Infectious Disease
Bethesda, MD

11:00 am – 11:30 am  Role of microRNAs in Health and Disease of the Immune System
Daniel Salomon, MD
Scripps Research Institute
La Jolla, CA

11:30 am – 12:00 pm  Engineering Lymphocyte Subsets for Clinical Trials
James Riley, PhD
University of Pennsylvania
Philadelphia, PA

12:00 pm – 1:00 pm  Lunch on Own

Clinical Update for the Basic Scientist
Moderators: Mandy Ford, PhD, Emory University, Atlanta, GA and Marisa Alegre, MD, PhD, University of Chicago, Chicago, IL

1:00 pm – 1:30 pm  New Approaches to Immunosuppression
Allan Kirk, MD, PhD
Emory University
Atlanta, GA

1:30 pm – 2:00 pm  Viral Nephropathies
Hans Hirsch, MD, MSc
University of Basel / Institute for Medical Microbiology
Basel

2:00 pm – 2:30 pm  Post-Transplant Lymphoproliferative Disease
Olivia Martinez, PhD
Stanford University
Stanford, CA

2:30 pm – 3:00 pm  Assays to Detect Tolerance
Peter Heeger, MD
Mt. Sinai School of Medicine
New York, NY

3:00 pm – 3:30 pm  Break

New Technologies for Clinical and Basic Scientists
Moderators: Alessandro Alessandrini, PhD, Massachusetts General Hospital, Boston, MA and Sheri Krams, PhD, Stanford University School of Medicine, Stanford, CA
3:30 pm – 4:00 pm  New Concepts in Polychromatic Flow Cytometry for Transplantation Research and Clinical Diagnostics  
Frederic Preffer, PhD  
Harvard Medical School & Massachusetts General Hospital  
Boston, MA

4:00 pm – 4:30 pm  Deep Sequencing and Genomics  
Daniel Salomon, MD  
Scripps Research Institute  
La Jolla, CA

4:30 pm – 5:00 pm  In Vivo Imaging  
Seok-Hyun Andy Yun, PhD  
Harvard Medical School and Massachusetts General Hospital  
Boston, MA

5:00 pm – 5:30 pm  New Technologies to Sequence Single Cell BCR or TCR in Blood or Tissues  
Patrick Wilson, PhD  
University of Chicago  
Chicago, IL

Essential Immunology for the Clinician (Full Day)

Key Players of the Immune Response  
Moderator: Lori West, MD, DPhil, University of Alberta, Edmonton, Canada

8:00 am – 8:30 am  How Does Rejection Occur?  
Fadi Lakkis, MD  
University of Pittsburgh, Starzl Transplant Institute  
Pittsburgh, PA

8:30 am – 9:00 am  Why T Cell Activation Matters: Applications to Human Transplant Recipients?  
Stuart Knechtle, MD, PhD  
Emory University School of Medicine  
Atlanta, GA

9:00 am – 9:30 am  B Cells and Plasma Cells: The Biology Behind the New Therapies  
Lori West, MD, DPhil  
University of Alberta
American Transplant Congress 2011 Preliminary Program

Edmonton, Canada

9:30 am – 10:00 am  Regulating the Immune Response: Does This Really Happen in People?  
Jonathan Bromberg, MD, PhD  
University of Maryland  
Baltimore, MD

10:00 am – 10:30 am  Coffee Break

Effector Mechanisms of Allograft Injury  
Moderator: Roslyn Mannon, MD, University of Alabama, Birmingham, AL

10:30 am – 11:00 am  Injury to the Epithelium: Fundamental Mechanisms and Clinical Applications  
Anthony Jevnikar, MD  
London Health Sciences Centre—University Hospital  
London, Canada

11:00 am – 11:30 am  Overview of Innate Immunity: Clinical Relevance  
William Baldwin, MD, PhD  
Cleveland Clinic Main Campus, Lerner Research Institute  
Cleveland, OH

11:30 am – 12:00 pm  Allograft Fibrosis: An Ends to the Means of Injury  
Roslyn Mannon, MD  
University of Alabama, Birmingham  
Birmingham, AL

12:00 pm – 1:00 pm  Lunch on Own

Clinical Applications of Basic Immunology: Part I  
Moderator: Martin Zand, MD, PhD, University of Rochester, Rochester, NY

1:00 pm – 1:30 pm  Understanding Immunosuppression: How the Drugs Really Work  
Martin Zand, MD, PhD  
University of Rochester  
Rochester, NY

1:30 pm – 2:00 pm  Update on Histocompatibility and Antibody Detection  
Elaine Reed, PhD  
University of California, Los Angeles  
Los Angeles, CA
2:00 pm – 2:30 pm    Transplant Tolerance: Fact or Fiction
Kenneth Newell, MD, PhD
Emory University
Atlanta, GA

2:30 pm – 3:00 pm    Break

Clinical Applications of Basic Immunology: Part II
Moderator: Thomas Mueller, MD, University of Alberta, Edmonton, Canada

3:00 pm – 3:30 pm    Gene Expression: The Technique, Molecules and their Application to Transplantation
Thomas Mueller, MD
University of Alberta
Edmonton, Canada

3:30 pm – 4:00 pm    Immune Monitoring: From Bench to Bedside?
Nader Najafian, MD
Brigham & Women’s Hospital
Boston, MA

4:00 pm – 4:30 pm    Responding to Viral Infection: Mechanisms and Consequences on Recipient Immunity and Allograft Injury
Atul Humar, MD
University of Alberta
Edmonton, Canada

Transplant Administrative Boot Camp Critical Elements: What Every Team Member Needs to Know (Full Day)

UNOS Regulations and Compliance
Moderators: Angelina Korsun, RN, MSN, MPA, Tampa General Hospital, Tampa, FL and Barry Friedman, RN, BSN, CPTC, University of Minnesota Medical Center—Fairview, Minneapolis, MN

8:00 am – 8:30 am    OPTN Rules Overview
UNOS MPSC Staffer

8:30 am – 9:00 am    Site Survey Preparation and Process
Janie Morrison, BHS
University Hospitals Case Medical Center
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am – 9:30 am</td>
<td>Maintaining Compliance</td>
<td>Betty Crandall, MS, RN</td>
<td>Sentara Norfolk General Hospital, Norfolk, VA</td>
</tr>
<tr>
<td>9:30 am – 10:00 am</td>
<td>Documentation Requirements</td>
<td>Betty Crandall, MS, RN</td>
<td>Sentara Norfolk General Hospital, Norfolk, VA</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 am – 11:00 am</td>
<td>SRTR Interpretation: SRTR Data Input Makers</td>
<td>Bertram Kasiske</td>
<td></td>
</tr>
<tr>
<td>11:00 am – 11:30 am</td>
<td>Wait List Management</td>
<td>Betty Crandall, MS, RN</td>
<td>Sentara Norfolk General Hospital, Norfolk, VA</td>
</tr>
<tr>
<td>11:30 am – 12:00 pm</td>
<td>QI Program in Practice</td>
<td>Linda Ohler</td>
<td>Georgetown University, Washington, DC</td>
</tr>
<tr>
<td>12:00 pm – 12:30 pm</td>
<td>Maintaining Compliance</td>
<td>Linda Ohler</td>
<td>Georgetown University, Washington, DC</td>
</tr>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td>Lunch on Own</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Quality Improvement Tools**

*Moderators: Tracey Evans-Walker, MSN, CNP, CCTC, Cleveland Clinic Foundation, Cleveland, OH and Bill Hasskamp, RN, BSN, CPTC, LifeShare of the Carolinas, Asheville, NC*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am – 11:00 am</td>
<td>SRTR Interpretation: SRTR Data Input Makers</td>
<td>Bertram Kasiske</td>
<td></td>
</tr>
<tr>
<td>11:00 am – 11:30 am</td>
<td>Wait List Management</td>
<td>Betty Crandall, MS, RN</td>
<td>Sentara Norfolk General Hospital, Norfolk, VA</td>
</tr>
<tr>
<td>11:30 am – 12:00 pm</td>
<td>QI Program in Practice</td>
<td>Linda Ohler</td>
<td>Georgetown University, Washington, DC</td>
</tr>
</tbody>
</table>

**Program Certification Requirements/CMS Rules**

*Moderators: Barry Friedman, RN, BSN, CPTC, University of Minnesota Medical Center, Minneapolis, MN and Renee Bennett, RN, BSN, Cleveland, OH*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm – 1:30 pm</td>
<td>Medicare Conditions of Participation: What You Need to Know</td>
<td>Gwen McNatt, RN, CNN, CFNP</td>
<td>Northwestern Memorial Hospital, Chicago, IL</td>
</tr>
<tr>
<td>1:30 pm – 2:00 pm</td>
<td>CMS Audit Survival: What Changes has this Caused with Hospitals and Patient Care</td>
<td>Jennifer Milton, BSN, MBA, CCTC</td>
<td>University of Texas Health Science Center, San Antonio, TX</td>
</tr>
<tr>
<td>2:00 pm – 2:30 pm</td>
<td>Comparing CMS and OPTN Rules</td>
<td>Kathy Schwab, BSN, RN</td>
<td>Mayo Clinic Foundation, Rochester, MN</td>
</tr>
<tr>
<td>2:30 pm – 3:00 pm</td>
<td>Moving Forward/Institutional Vision and Commitment</td>
<td>Timothy Pruett, MD</td>
<td>University of Minnesota, Minneapolis, MN</td>
</tr>
<tr>
<td>3:00 pm – 3:30 pm</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 pm – 4:00 pm</td>
<td>Transplant Center Fiscal Issues and Compliance</td>
<td>Gene Ridolfi, RN, BA</td>
<td>Washington University School of Medicine, St. Louis, MO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Angelina Korsun, RN, MSN, MPA</td>
<td>Tampa General Hospital, Tampa, FL</td>
</tr>
<tr>
<td>3:30 pm – 4:00 pm</td>
<td>Medicare Cost Report Review</td>
<td>Edward Zavala, MBA</td>
<td>Vanderbilt Transplant Center, Nashville, TN</td>
</tr>
<tr>
<td>4:00 pm – 4:30 pm</td>
<td>Cost Reporting: Common Errors</td>
<td>Edward Zavala, MBA</td>
<td>Vanderbilt Transplant Center, Nashville, TN</td>
</tr>
<tr>
<td>4:30 pm – 5:00 pm</td>
<td>Time Studies and Documentation</td>
<td>Alexander Aussi, BSN, RN</td>
<td>University of California, San Diego Medical Center, San Diego, CA</td>
</tr>
<tr>
<td>5:00 pm – 5:30 pm</td>
<td>Fiscal Monitoring of Your Transplant Program</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Troubled Renal Allograft—ARS (Don Hricik) (Half-Day Morning)

Moderators: Roy Bloom, MD, Hospital of the University of Pennsylvania, Philadelphia, PA and Michelle Josephson, MD, University of Chicago, Chicago, IL

Predictors of Outcome
8:00 am – 8:30 am  Histological Predictors: Lessons from the DEKAF Study
                    Arthur Matas, MD
                    University of Minnesota
                    Minneapolis, MN

8:30 am – 9:00 am  Genomic Recognition of the Troubled Allograft
                    Sunil Kurian, PhD
                    The Scripps Research Institute
                    La Jolla, CA

9:00 am – 9:30 am  Predictors of Antibody-mediated Injury
                    Philip Halloran, MD
                    University of Alberta
                    Edmonton, Canada

9:30 am – 10:00 am Early Biomarkers as Surrogates for Long-term Outcomes
                    David Rush, MD
                    University of Manitoba
                    Winnipeg, Canada

10:00 am – 10:30 am Coffee Break

Managing the Failing/Failed Renal Allograft

10:30 am – 11:00 am Should CKD Guidelines Apply to Kidney Transplant Recipients?
                    TBD

11:00 am – 11:30 am Tapering Immunosuppression after Graft Failure
                    John Gill, MD, MS
                    St. Paul’s Hospital
                    Vancouver, Canada

11:30 am – 12:00 pm Pros and Cons of Allograft Nephrectomy
                    J. Harold Helderman, MD
                    Vanderbilt University Medical Center
American Transplant Congress 2011 Preliminary Program

Nashville, TN

Leading Practices in Organ Donation & Preservation (Half-Day Morning)

Understanding the Donor Pool, OPO Performance and Organ Utilization
Moderators: David Mulligan, MD, Mayo Clinic Arizona, Phoenix, AZ and Charles Alexander, RN, MSN, MBA, CPTC, The Living Legacy Foundation of Maryland, Baltimore, MD

8:00 am – 8:30 am  Evaluating the Donor Pool: How Many Potential Donors Are There Really?
Richard Hasz, MFS, CPTC
Gift of Life Donor Program
Philadelphia, PA

8:30 am – 9:00 am  Improving Transplant Per Donor
John Rosendale, MS
United Network for Organ Sharing
Richmond, VA

9:00 am – 9:30 am  Kidney Utilization: How Many More Kidneys Could Be Used That Are Already Procured?
Francis Delmonico, MD
Harvard Medical School
Boston, MA

9:30 am – 10:00 am  DCD Update in the United States: Improving DCD Outcomes
Christopher Hughes, MD
Emory University
Atlanta, GA

10:00 am – 10:30 am  Coffee Break

Emerging Practices to Improve Donation and Transplantation Outcomes
Moderators: Kenneth Brayman, MD, PhD, University of Virginia Health System, Charlottesville, VA and Howard Nathan, Gift of Life Donor Program, Philadelphia, PA

10:30 am – 11:00 am  Ex Vivo Lung Preservation and Resuscitation
Marcelo Cypel

11:00 am – 11:30 am  Composite Tissue Donation and Transplantation: Now and The Future
L. Scott Levin, MD, FACS
University of Pittsburgh Medical Center
Pittsburgh, PA

11:30 am – 12:00 pm Improving Donor Management, Implications for Research and Transplant Outcomes
Sandy Feng, MD, PhD
University of California, San Francisco
San Francisco, CA

12:00 pm – 12:30 pm Utilization of State Donor Registries to Improve Authorized Rates in Organ Donation
Kevin O’Connor, MD
Life Center Northwest
Seattle, WA

Clinical Trials in Pediatric Solid Organ Transplantation (Half-Day Morning)

Pediatric Trials: Do We Need Them? How Do We Overcome the Barriers?
Moderators: Anne Dipchand, MD, The Hospital of Sick Children, Toronto, Canada

8:00 am – 8:30 am Debate #1
8:00 am – 8:09 am Prospective Clinical Trials are the Only Option
William Harmon, MD
Harvard Medical School
Boston, MA

8:09 am – 8:18 am Clinical Trials in Children are Doomed to Failure
Robert Shaddy
Children’s Hospital of Philadelphia
Philadelphia, PA

8:18 am – 8:20 am Rebuttals

8:20 am – 8:30 am Discussion

8:30 am – 9:00 am The Contribution of Clinical Trials to the Understanding of the Science of Transplantation
Sandy Feng, MD, PhD
University of California, San Francisco
San Francisco, CA

9:00 am – 9:30 am Methodological and Practical Challenges of Research in Children
Rulan Parekh
9:30 am – 10:00 am  Ethical Considerations in Research in Children in the Context of End-Stage Organ Failure and Organ Transplantation
Richard Thistlethwaite, Jr., MD, PhD
University of Chicago
Chicago, IL

10:00 am – 10:30 am  Coffee Break

Lessons Learned from Pediatric Trials and Looking to the Future
Moderators: Estela Azeka, MD, Heart Institute (InCor), Sao Paulo, Brazil and Richard Trompeter, MD, Great Ormond Street Hospital for Children, London, United Kingdom

10:30 am – 11:00 am  Debate #2

10:30 am – 10:39 am   There is Still a Role for Registries in Pediatric Solid Organ Transplantation (Pro)
Steven Webber

10:39 am – 10:48 am   There is Still a Role for Registries in Pediatric Solid Organ Transplantation (Con)
Richard Kirk
Newcastle Freeman Hospital
London, UK

10:48 am – 10:50 am  Rebuttals

10:50 am – 11:00 am  Discussion

11:00 am – 11:30 am  “TWIST”: Lessons Learned and What I Would have Done Differently
Ryszard Grenda, MD
Children’s Memorial Health Institute
Warsaw, Poland

11:30 am – 12:00 pm  CCTPT: Lessons Learned
Mark Benfield, MD
Pediatric Nephrology of Alabama
Birmingham, AL

12:00 pm – 12:30 pm  The Role of the NIH in Pediatric Solid Organ Transplant Research: Present and Future
TBD
Essentials in Transplant Infectious Diseases: An Interactive Case-Based Session (ARS) (Half-Day Afternoon)

Moderators: Emily Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA and Marian Michaels, MD, MPH, Children’s Hospital of Pittsburgh, Pittsburgh, PA

1:00 pm – 1:25 pm   What’s New in Molecular Diagnostics?
Jutta Preiksaitis, MD
Provincial Lab Public Health
Edmonton, Canada

1:30 pm – 1:55 pm   What’s New in the Bacteriology Lab? New Technology, New Bugs, New Breakpoints
Robin Patel, MD
Mayo Clinic
Rochester, MN

2:00 pm – 2:25 pm   Respiratory Viruses in Transplantation
Lara Danziger-Isakov, MD, MPH
Center for Pediatric Infectious Diseases, Children’s Hospital at Cleveland Clinic
Cleveland, OH

2:30 pm – 3:00 pm   Dermatologic Manifestations of Infection: What the Skin Can Reveal in Our Immunosuppressed Patients (Cases 1)
Carrie Kovarik, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

3:00 pm – 3:30 pm   Break

3:30 pm – 3:55 pm   Human Herpesvirus 6 and 7: Real Pathogens?
Vincent Emery, MD
University College of London
London, United Kingdom

4:00 pm – 4:25 pm   XMRV Infection: What is the Data? Why Our Patients Are So Tired?
Michael Ison, MD, MS
Northwestern University
American Transplant Congress 2011 Preliminary Program

Chicago, IL

4:30 pm – 5:30 pm "Stump the Stars" (Cases 2): Great Cases in Transplant ID
Camille Kotton, MD
Massachusetts General Hospital
Boston, MA

Upton Allen, MBBS, MSc
University of Toronto
Toronto, Canada

Emily Blumberg, MD
Hospital of the University of Pennsylvania
Philadelphia, PA

Update on Immunosuppression (Half-Day Afternoon)
Moderators: Simin Goral, MD, University of Pennsylvania, Philadelphia, PA and
Kenneth Brayman, MD, PhD, University of Virginia Health System, Charlottesville, VA

1:00 pm – 1:30 pm Should Induction Antibody Therapy be Individualized?
Daniel Brennan, MD
Washington University in St. Louis
St. Louis, MO

1:30 pm – 2:00 pm Pros and Cons of Alemtuzumab
Stuart Knechtle, MD, PhD
Emory University School of Medicine
Atlanta, GA

2:00 pm – 2:30 pm Steroid Minimization
Joshua Augustine, MD
University Hospitals Case Medical Center
Cleveland, OH

2:30 pm – 3:00 pm Calcineurin Inhibitor Minimization
Stephen Tomlanovich, MD
University of California, San Francisco
San Francisco, CA

3:00 pm – 3:30 pm Break

3:30 pm – 4:00 pm Optimal Use of TOR Inhibitors
Alexander Wiseman, MD
University of Colorado of Denver HSC
Aurora, CO
4:00 pm – 4:30 pm  Clinical Tolerance Protocols  
**John Friedewald, MD**  
*Northwestern University*  
*Chicago, IL*

4:30 pm – 5:00 pm  New Immunosuppressants in the Pipeline  
**Herwig-Ulf Meier-Kriesche, MD**  
*University of Florida*  
*Gainesville, FL*

### Critical Care Issues in Liver Transplantation (Half-Day Afternoon) ARS  
(Levitsky)

#### “Keeping the Patient Transplantable”

*Moderators: Josh Levitsky, MD, Northwestern Memorial Hospital, Chicago, IL and Gregory Everson, MD, University of Colorado Denver, Aurora, CO*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:00 pm – 1:30 pm | Life-Saving Interventions in Acute and Chronic Liver Failure  
**Arun Sanyal, MD**  
*Virginia Commonwealth University*  
*Richmond, VA* |
| 1:30 pm – 2:00 pm | Cardiopulmonary Assessment  
**Michael Ramsay, MD, FRCA**  
*Baylor University Medical Center*  
*Dallas, TX* |
| 2:00 pm – 2:30 pm | ICU Management of the Wait-Listed Patient  
**Ram Subramanian, MD**  
*Emory University School of Medicine*  
*Decatur, GA* |
| 2:30 pm – 3:00 pm | When is a Patient Too Sick to Transplant?  
**Randolph Steadman, MD, PhD**  
*University of California, Los Angeles Medical Center*  
*Los Angeles, CA* |
| 3:00 pm – 3:30 pm | Break |

### Management Dilemmas in the Transplant Recipient

*Moderators: David Foley, MD, University of Wisconsin, Madison, WI and W. Kenneth Washburn, MD, University of Texas HSC, San Antonio, TX*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 3:30 pm – 4:00 pm | Key Aspects of Anesthesia and Intra-operative Care  
**Andre De Wolf, MD**  
*Northwestern University* |
Chicago, IL

4:00 pm – 4:30 pm
Protecting the Kidney
Claus Niemann, MD
University of California, San Francisco
San Francisco, CA

4:30 pm – 5:00 pm
Management of Early Graft Dysfunction and Surgical Complications
Zoe Stewart, MD, PhD
University of Iowa Hospitals and Clinics
Iowa City, IA

5:00 pm – 5:30 pm
The “Right” Amount of Immunosuppression in Specific Disease States
Hans Schlitt, MD
Klinkum Der Universitat Regensburg
Regensburg, Germany

Early Post Operative Complications (Half-Day Afternoon)

Renal Allograft Dysfunction
Moderators: Mark Burns, FNP, ACNP, Mayo Clinic Hospital, Gilbert, AZ and Deborah Hoch, DNP, Maine Medical Center, Portland, ME

1:00 pm – 1:30 pm
Rejection
Milagros Samaniego, MD
University of Michigan Medical School
Ann Arbor, MI

1:30 pm – 2:00 pm
Surgical Complications
Peter Kennealey, MD
Denver, CO

2:00 pm – 2:30 pm
Medication as the Culprit in Acute Renal Allograft Dysfunction
John Vella, MD
Maine Medical Center
Portland, ME

2:30 pm – 3:00 pm
Hematologic Complications Post Renal Transplant: The Anemia’s
Douglas Keith, MD
University of Virginia Medical Center
Gordonsville, VA
3:00 pm – 3:30 pm Break

Liver Allograft Dysfunction
Moderators: Sharon Blashka and Denise Morin, MSN, RN, Lahey Clinic, Burlington, MA

3:30 pm – 4:00 pm Rejection
Jennifer Cademartori, FNP-BC
University of California, San Francisco
San Francisco, CA

4:00 pm – 4:30 pm Surgical Complications
Peter Abt, MD
Hospital of the University of Pennsylvania
Philadelphia, PA

4:30 pm – 5:00 pm Infections, Non-Recurent Disease
Costi Sifri, MD
University of Virginia School of Medicine
Charlottesville, VA

5:00 pm – 5:30 pm Infections, Recurrent Disease
Josh Levitsky MD
Northwestern Memorial Hospital
Chicago, IL
ATC 2011 ANNUAL MEETING

OPENING RECEPTION & EXHIBITS
5:30 pm - 7:00 pm

POSTER SESSION I
5:30 pm – 7:00 pm

SUPPORTER EVENT
7:30 pm
**SUNRISE SYMPOSIA**

**HIV & Transplantation: What Have We Learned and Where Are We Going?**

*Moderators: Barbara Murphy, MD, Mt. Sinai School of Medicine, New York, NY and Peter Chin-Hong, MD, University of California, San Francisco, CA*

- 7:00 am – 7:25 am  
  Update and Unexpected Results in the HIV-positive Solid Organ Transplantation: Do We Need to Change Selection Criteria?  
  *Peter Stock, MD, PhD*  
  *University of California, San Francisco*  
  *San Francisco, CA*

- 7:25 am – 7:50 am  
  HIV Therapy and Minimizing Rejection in a New Era of Antiretroviral Therapy  
  *George Beatty, MD*  
  *University of California, San Francisco*  
  *San Francisco, CA*

- 7:50 am – 8:15 am  
  Expanding the Donor Pool Further: Transplanting Organs from HIV-positive Donors to HIV-positive Recipients  
  *Elmi Muller, MD*

**CD8 Cells: Suppressors and Effectors**

*Moderators: Alessandro Alessandrini, PhD, Massachusetts General Hospital, Boston, MA and Tatsuo Kawai, MD, Massachusetts General Hospital, Boston, MA*

- 7:00 am – 7:25 am  
  Induction of Regulatory CD8+ T Cells for Use in Transplantation  
  *Nicole Suciu-Foca*

- 7:25 am – 7:50 am  
  Phenotypic and Functional Differences of Effector and Regulatory CD8 T Cells  
  *Zhenhua Dai*

- 7:50 am – 8:15 am  
  The Role of CD8 Effector T Cells in Transplantation in Primates  
  *Tatsuo Kawai, MD*
Controversies in Transplant Pharmacy Practice
Moderators: Eric Tichy, PharmD, Yale-New Haven Hospital, New Haven, CT and Andrew Silverman, PharmD, Tampa General, Tampa, FL

7:00 am – 7:25 am  Generic Medications in Transplantation
Lisa McDevitt-Potter, PharmD
Tufts Medical Center
Boston, MA

7:25 am – 7:50 am  Billing for Transplant Pharmacy Services
Angela Maldonado, PharmD
Providence Sacred Heart Medical Center
Spokane, WA

7:50 am – 8:15 am  Risk Evaluation and Mitigation Strategies (REMS) and Their Implications in Organ Transplantation
Steven Gabardi, PharmD
Brigham & Women’s Hospital
Boston, MA

Deceased Donor Kidney Utilization and the Prospect of Ex-Vivo Repair
Moderators: Francis Delmonico, MD, Harvard Medical School, Boston, MA and Kevin O’Connor, MD, LifeCenter Northwest, Seattle, WA

7:00 am – 7:25 am  Kidney Discard: New Data by Donor Risk Index
John Rosendale, MS
United Network for Organ Sharing
Richmond, VA

7:25 am – 7:50 am  Kidney Repair Starts in the Donor
Henri Leuvenik, PhD
University Medical Center Groningen
Groningen, The Netherlands

7:50 am – 8:15 am  Kidney Transplantation: Improving Utilization
Stefan Tullius, MD, PhD
Brigham & Women’s Hospital
Boston, MA
Infection and Allograft Survival: “Indirect Effects”
Moderators: Atul Humar, MD, University of Alberta, Edmonton, Canada and Richard Freeman, MD, Dartmouth Medical School, Hanover, NH

7:00 am – 7:25 am  Heterologous Immunity and Graft Rejection  
Andrew Adams, MD, PhD  
Emory University  
Atlanta, GA

7:25 am – 7:50 am  Respiratory Viruses and Rejection  
Michael Ison, MD, MS  
Northwestern University  
Chicago, IL

7:50 am – 8:15 am  Community Acquired Respiratory Viruses in Lung Transplantation  
Todd Astor

Preclinical and Clinical Application of Regulatory T Cells in Transplantation Tolerance
Moderators: Li Zhang, MD, MSc, University Health Network, Toronto General Hospital, Toronto, Canada and Sandy Feng

7:00 am – 7:25 am  Regulatory T Cell Therapy for Transplantation Tolerance  
Robert Lechler, PhD  
King’s College London  
London, United Kingdom

7:25 am – 7:50 am  Regulatory T Cells in Transplantation: Bad and Good Guys  
Hans-Dieter Volk, MD, PhD  
Institute of Medical Immunology  
Berlin, Germany

7:50 am – 8:15 am  Clinical Trials of Tr1 Cells  
Kevan Herold

T Cell Immunity in Clinical Practice
Moderators: Hans Hirsch and Martina Sester, PhD, University of the Saarland, Homburg, Germany

7:00 am – 7:25 am  Principles of Antigen-specific T Cell Assays for the Use in Clinical Routine  
Deepali Kumar, MD
American Transplant Congress 2011 Preliminary Program

University of Alberta
Edmonton, Canada

7:25 am – 7:50 am  Physiological Changes in T Cells with Increasing Age: The Role of Infections
Graham Pawelec, MA, PhD
Medizinische Universitatsklinik Tuebingen
Tuebingen, Germany

7:50 am – 8:15 am  Potential Application of Antigen-specific T Cell Analyses in Transplant Recipients: Improving Control of Infection and Beyond?
Urban Sester, MD
Saarland University
Homburg, Germany

Tolerance in Clinical Transplantation through Mixed Chimerism: Update on Trials?
Moderators: Kenneth Brayman, MD, PhD, University of Virginia Health System, Charlottesville, VA and Suzanne Ildstad, MD, University of Louisville, Louisville, KY

7:00 am – 7:25 am  Mixed Chimerism in Human Kidney Recipients: An Update
A. Benedict Cosimi, MD
Massachusetts General Hospital
Boston, MA

7:25 am – 7:50 am  Kidney Transplant Tolerance at Stanford using TLI, ATG and HCT
John Scandling, MD
Stanford University
Palo Alto, CA

7:50 am – 8:15 am  Improving Kidney Graft Tolerance with FC Enriched HSC’s
Joseph Leventhal, MD, PhD
Northwestern University Medical School
Chicago, IL

The Latest in Extreme Kidney Transplantation—ARS (Dorry Segev)
Moderators: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD and Lloyd Ratner, MD, Columbia University, New York, NY
7:00 am - 7:25 am  Fully Robotic Intra-peritoneal Kidney Transplant in Obese Recipients  
Enrico Benedetti, MD  
University of Illinois—Chicago  
Chicago, IL

7:25 am – 7:50 am  Deceased Donor Kidney Transplantation from Donors on Dialysis  
Niraj Desai, MD  
Johns Hopkins  
Baltimore, MD

7:50 am – 8:15 am  Double Kidney Transplantation: Indications and Ipsilateral Technique  
Osama Gaber, MD  
The Methodist Hospital/Cornell University  
Houston, TX

EARLY MORNING WORKSHOPS – TICKETED EVENT

1. Assessment of Coagulation in End Stage Liver Disease: Pitfalls and Solutions  
Moderators: Robert Porte, MD, PhD, University Medical Center Groningen, Groningen, Canada and Steven Caldwell, MD, University of Virginia, Salt Lake City, VA

2. Donation after Circulatory Determination of Death (DCDD) in Children: The Ethics, The Process and the Outcomes  
Moderators: Thomas Nakagawa, MD, Wake Forest University Baptist Medical Center and Susan Bratton, MD, University of Utah, Stanford, UT

3. Grant Writing Workshop for Basic Science and Clinical Fellows  
Moderators: David Rothstein, MD, Thomas E. Starzl Transplant Institute, Pittsburgh, PA and Marisa Alegre, MD, PhD, University of Chicago, Chicago, IL

4. KDIGO Practice Guidelines in Transplant: How and When Should We Use Them, When Should We Not?  
Moderators: Bertram Kasiske, MD, Hennepin County Medical Center, Minneapolis, MN and John Gill, MD, St. Paul’s Hospital, Vancouver, Canada
5. Surrogate Endpoints in Transplantation
Moderators: Jesse Schold, PhD, M. Stat, M. Ed, Cleveland Clinic Foundation, Cleveland, OH and Greg Knoll, MD, The Ottawa Hospital, Ottawa, Canada

6. The Transplanted Woman: Issues to Consider
Moderators: Vincent Armenti, MD, PhD, Thomas Jefferson University, Philadelphia, PA and Veronica Gomez-Lobo, MD, Georgetown University, Washington Hospital Center, Washington, DC

7. The Current Status of Islet Transplantation
Moderators: Bernhard Hering, MD, University of Minnesota, Minneapolis, MN and Ali Naji, MD, University of Pennsylvania Hospital, Philadelphia, PA

8. What Do Animal Models Tell Us About Chronic Rejection?
Moderators: D. Keith Bishop, PhD, University of Michigan Medical Center, Ann Arbor, MI and William Baldwin, MD, PhD, Cleveland Clinic Main Campus, Lerner Research Institute, Cleveland, OH

BREAK
8:15 am – 8:30 am

JOINT PLENARY AND AWARDS
8:30 am – 9:45 am

CONTROVERSIES IN TRANSPLANTATION—ARS (DORRY SEGEV)
9:45 am – 10:45 am

Geographic Disparities in Liver Transplantation and Novel Approaches for Addressing Them
Moderators: Krista Lentine, MD, St. Louis, MO and Goran Klintmalm, MD, PhD, Baylor Regional Transplant Institute, Dallas, TX

9:45 am – 10:00 am  The Case for Redistribution
James Markmann, MD, PhD
Massachusetts General Hospital
**American Transplant Congress 2011 Preliminary Program**

**Boston, MA**

10:00 am – 10:15 am  Economics of Redistribution  
Mark Schnitzler, PhD  
Saint Louis University School of Medicine  
St. Louis, MO

10:15 am – 10:30 am  Mathematical Tools to Design Redistribution  
Sommer Gentry, MD, PhD  
U.S. Naval Academy, Annapolis, MD

10:30 am – 10:45 am  Panel Discussion

**COFFEE BREAK**  
10:45 am – 11:00 am

**MIDDAY SYMPOSIA**

**B Lymphocyte/Plasma Cell Homeostasis in Transplantation**  
**Moderators:** Michael Cancro, PhD, University of Pennsylvania, Philadelphia, PA and Anita Chong, PhD, University of Chicago, Chicago, IL

11:00 am – 11:30 am  B Lymphocyte/Plasma Cell Development, Selection and Homeostasis  
Michael Cancro, PhD  
University of Pennsylvania  
Philadelphia, PA

11:30 am – 12:00 pm  Plasma Cell and Memory B Cells: Implications for Transplantation  
David Tarlinton, PhD  
The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

12:00 pm – 12:30 pm  B Cell Repertoire Directed Approaches for Tolerance in Transplantation  
Hooman Noorchashm, MD, PhD  
University of Pennsylvania  
Philadelphia, PA

**Biomarkers as Diagnostic and Prognostic Tools in Organ Transplantation**  
**Moderators:** Valeria Mas, PhD, Virginia Commonwealth University, Glen Allen,
VA and Thomas Mueller, MD, University of Alberta, Edmonton, Canada

11:00 am – 11:30 am  Biomarkers Discovery and Clinical Application: Why is There Such a Gap?  
   Daniel Salomon, MD  
   Scripps Research Institute  
   La Jolla, CA

11:30 am – 12:00 pm  Biomarkers of Acute Rejection: Where Are We?  
   Manikkan Suthanthiran, MD  
   New York Presbyterian Hospital—Cornell  
   New York, NY

12:00 pm – 12:30 pm  Biomarkers to Predict Outcomes: Is it Possible?  
   Peter Heeger, MD  
   Mt. Sinai School of Medicine  
   New York, NY

New Insights in Fibrogenesis and Tissue Injury
Moderators: Robert Fairchild, PhD, Cleveland Clinic Foundation, Cleveland, OH and Geetha Chalasani, PhD, University of Pittsburgh, Pittsburgh, PA

11:00 am – 11:30 am  Identification of the Transitional Fibrogenic Cells  
   Benjamin Humphreys, MD, PhD  
   Brigham & Women’s Hospital  
   Boston, MA

11:30 am – 12:00 pm  Linking Lung Inflammation and Fibrosis  
   A.P. Fontenot, MD  
   University of Colorado—Denver  
   Aurora, CO

12:00 pm – 12:30 pm  CTGF and Other Factors in Fibrosis  
   Roslyn Mannon, MD  
   University of Alabama, Birmingham  
   Birmingham, AL

Innovative Strategies to Protect the DCD Liver—ARS (Foley)
Moderators: David Foley MD, University of Wisconsin, Madison, WI and John Renz, MD, PhD, University of Arizona, Tucson, AZ

11:00 am – 11:22 am  The DCD Liver Experience to Date: Outcome and Cost Implications of DCD Liver Transplantation  
   Talia Baker, MD
Northwestern Memorial Hospital
Chicago, IL

11:22 am – 11:44 am  Ex Vivo Normothermic Perfusion of DCD Livers
Peter Friend, MD
University of Oxford
Oxford, United Kingdom

11:44 am – 12:06 pm  Ex Vivo Perfusion of DCD Livers
Pierre Clavien, MD, PhD
University Hospital Zurich
Zurich, Switzerland

12:06 pm – 12:28 pm  Role of Thrombolytic Therapy in DCD Livers: Use in Donor, Recipient or Both?
John Fung, MD, PhD
Cleveland Clinic Foundation
Cleveland, OH

Update and Future Directions of New Immunosuppressive Therapies in Renal Transplantation
Moderators: Bruce Kaplan, MD, AHSC, Tucson, AZ and Chris Larsen, MD, PhD, Emory University, Atlanta, GA

11:00 am – 11:30 am  Ongoing trials with immunosuppressive agents in the pipeline
Herwig-Ulf Meier-Kreische, MD
University of Florida
Gainesville, FL

11:30 am – 12:00 pm  Current Status of the Costimulatory Blockade Agents
Josep Maria Grinyo, MD, PhD
University of Barcelona
Barcelona, Spain

12:00 pm – 12:30 pm  Biologic Agents: Opportunities to Affect Novel Pathways for Immunosuppression
Flavio Vincenti, MD
University of California, San Francisco
San Francisco, CA

Novel Antivirals in the Pipeline for HCV: Implications for Transplantation
Moderator: Josh Levitsky, MD, Northwestern Memorial Hospital, Chicago, IL
Overview of Novel Antivirals for HCV: The Immediate and Distant Future  
Norah Terrault, MD, MPH  
University of California, San Francisco  
San Francisco, CA

New HCV Therapy in the Transplant Setting: Forward Stride or Slippery Slope?  
Greg Everson, MD  
University of Colorado, Denver  
Denver, CO

Panel Discussion

Peter Stock, MD, PhD,  
University of California, San Francisco, San Francisco, CA;  
Kimberly Brown, MD,  
Henry Ford Hospital, Detroit, MI;  
Rajender Reddy, MD,  
University of Pennsylvania, Philadelphia, PA

Featured Symposium: Infectious Diseases Update for Pediatric Solid Organ Transplant Recipients

Moderators: Patricia Birk, MD, Children’s Hospital of Winnipeg, Winnipeg, Canada and Simon Horslen, MB, ChB, Seattle Children’s Hospital, Seattle, WA

Top Ten Update for Pediatrics form the 2nd Edition of Infectious Disease Guidelines for Transplant Recipients  
Upton Allen, MBBS, MSc  
University of Toronto  
Toronto, Canada

Emerging and Opportunistic Infections  
Marian Michaels, MD, MPH  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA

Evaluation and Management of Pediatric Solid Organ Transplant Recipients with BK & EBV: Two Interesting Cases  
Abhay Vats, MD  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA
Featured Symposium: Xenotransplantation: Lessons for Allotransplantation

Moderators: Gilles Benichou, MD, PhD, Massachusetts General Hospital, Boston, MA and Pierre Gianello, MD, PhD, University of Louvain, Brussels, Belgium

11:00 am – 11:20 am  Accommodation: Lessons from Xenotransplantation
Anthony Dorling, PhD, FRCP
King’s College London
London, Canada

11:20 am – 11:40 am  Donor-derived Infections: Is Risk Greater with Allotransplantation?
Jay Fishman, MD
Massachusetts General Hospital
Boston, MA

11:40 am – 12:00 pm  Innate Immunity: What are NK Cells Doing in Allotransplantation?
Joerg Seebach, MD
University Hospital and Medical Faculty Geneva
Geneva, Switzerland

12:00 pm – 12:20 pm  Coagulation and Coagulopathy: Endothelium and Transplantation
Simon Robson, MD, PhD
Beth Israel Deaconess Medical Center
Boston, MA

BREAK
12:30 pm – 12:45 pm

INDUSTRY LUNCHEON
12:45 pm – 2:00 pm

BREAK
2:00 pm – 2:15 pm
CONCURRENT ABSTRACT SESSIONS
2:15 pm – 3:45 pm

Concurrent Session 1: Acute Rejection
Concurrent Session 2: Allocation and Distribution
Concurrent Session 3: Biomarkers and Molecular Markers in Transplantation
Concurrent Session 4: Cardiovascular
Concurrent Session 5: Donor Kidney Index, Ischemia Time, Allocation
Concurrent Session 6: Effector Mechanisms of Chronic Rejection
Concurrent Session 7: Infections / Malignancy
Concurrent Session 8: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols I
Concurrent Session 9: Liver Recurrent Disease, Hepatitis, Liver Transplantation
Concurrent Session 10: Lung Transplant: Pushing the limits
Concurrent Session 11: Pancreas Transplant: Immunosuppression and Evaluation
Concurrent Session 12: Pathological Correlates and Allograft Failure

STUDENT PROGRAM
2:15 pm – 5:30 pm

The Science, the Art and the Allure of Transplantation: An Educational Session Designed for Medical Students and Residents
Moderator: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD

Fundamental Concepts of Transplantation
2:15 pm – 2:30 pm Immunosuppression: How It Works and Why We Need It
American Transplant Congress 2011 Preliminary Program

Dorry Segev, MD, PhD
Johns Hopkins University
Baltimore, MD

2:30 pm – 2:45 pm
Transplant Surgery: It All Started in 1954
Richard Freeman, MD
Dartmouth Medical School
Hanover, NH

2:45 pm – 3:00 PM
Nephrology and Kidney Transplantation: Better than Dialysis
John Gill, MD, MS
St. Paul’s Hospital
Vancouver, Canada

3:00 pm – 3:15 pm
Hepatology and Liver Transplantation: The Ultimate Treatment
Kimberly Olthoff, MD
University of Pennsylvania Hospital
Philadelphia, PA

3:15 pm – 3:30 pm
Coffee Break

3:30 pm – 3:45 pm
ID: It Only Gets Interesting When You Suppress the Immune System
Jay Fishman, MD
Massachusetts General Hospital
Boston, MA

3:45 pm – 4:00 pm
Heart/Lung: It Doesn’t Get Much More Invasive Than This
Anne Dipchand, MD
The Hospital of Sick Children
Toronto, Canada

4:00 pm – 4:15 pm
Pediatrics: Pediatric Transplants Are Not Just Little Organs
Jodi Smith, MD, MPH
Seattle Children’s Hospital
Seattle, WA

4:15 pm – 4:30 pm
Laboratory Research: B Cells, T Cells, Omics, Gene Therapy, You Name It
Allan Kirk, MD, PhD
Emory University
Atlanta, GA

4:30 pm – 4:45 pm
Clinical Research: What Other Field Has a National Registry of 200,000 Patients?
American Transplant Congress 2011 Preliminary Program

Krista Lentine, MD
St. Louis, MO

Why I Love It
4:45 pm – 5:30 pm Panel: Why I Love It

4:45 pm – 4:54 pm Jayme Locke, MD, MPH
Johns Hopkins Medical Institutions
Baltimore, MD

4:54 pm – 5:03 pm Peter Reese

5:03 pm – 5:12 pm Michael Englesbe

5:12 pm – 5:21 pm Alan Leichtman

5:21 pm – 5:30 pm Sandy Feng

ALLIED HEALTH SYMPOSIUM
3:00 pm – 4:30 pm

Are We Speaking the Same Language? Transplant Education and Consent
Moderators: Roxanne Taylor, RN, MSN, Maine Medical Center, Portland, ME and Ashley Seawright, DNP, ACNP-BC, University of Mississippi Health Care

3:00 pm – 3:30 pm Defining Informed Consent in Transplantation
Maryam Valapour, MD
University of Minnesota
Minnesota, MN

3:30 pm – 4:00 pm Assessing Learning Readiness
Roy Bloom

4:00 pm – 4:30 pm Overcoming Cultural Barriers
David Radosevich, RN, PhD
University of Minnesota
Minnesota, MN

TRANSPLANTATION IN DEPTH
2:15 pm – 5:00 pm
Antibody Mediated Rejection: Pathogenesis, Prevention and Treatment—ARS (Dorry Segev)

Moderators: Stanley Jordan, MD, Cedars Sinai Medical Center, Los Angeles, CA and Mark Stegall, MD, Mayo Clinic, Rochester, MN

2:15 pm – 2:35 pm How Does Donor Specific Antibody Develop and How Does It Cause Injury?
Kathryn Tinckam, MD, MMSc, FRCPC
University Health Network
Toronto, Canada

2:35 pm – 2:55 pm The Pathologic Criteria of Antibody Mediated Injury: A Critical Analysis
Lorraine Racusen, MD
Johns Hopkins Medical Institutions
Baltimore, MD

2:55 pm – 3:15 pm Defining the Clinical Presentation of Antibody Mediated Rejection: Early versus Late
Denis Glotz

3:15 pm – 3:35 pm How Should Antibody Mediated Rejection be Treated?
Denis Glotz

3:35 pm – 3:55 pm Monitoring for DSA: Risks and Benefits
Howard Gebel, PhD
Emory University Hospital
Atlanta, GA

3:55 pm – 4:10 pm Break

4:10 pm – 5:00 pm Debate: Swap or Desensitize? What’s the Right Way to Go?

4:10 pm – 4:30 pm Desensitization
Robert Montgomery, MD, DPhil
Johns Hopkins University
Baltimore, MD

4:30 pm – 4:50 pm Paired Kidney Donation
Adam Bingaman, MD, PhD
Methodist Specialty and Transplant Hospital
San Antonio, TX

4:50 pm – 5:00 pm Moderated Discussion
BREAK
3:45 pm – 4:00 pm

CONCURRENT ABSTRACT SESSIONS
4:00 pm- 5:30 pm

Concurrent Session 13: Acute Cellular Rejection
Concurrent Session 14: Expanding Utilization, Decreasing CIT, Virtual Crossmatch
Concurrent Session 15: Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies I
Concurrent Session 16: Immune Mediated Mechanisms
Concurrent Session 17: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols II
Concurrent Session 18: Outcomes and Complications after Cardiac Transplantation
Concurrent Session 19: Pancreas Transplantation: Clinical Management and Complications
Concurrent Session 20: Surgical / RAS / Retransplant
Concurrent Session 21: Therapeutic Approaches and Chronic Rejection
Concurrent Session 22: Tolerance: Clinical Studies
Concurrent Session 23: Viruses and Vaccines: In Memory of Mark Pescovitz, MD (1955-2010)

POSTER SESSION II
5:30 pm – 6:30 pm

INDUSTRY EVENT
7:00 pm
Monday, May 2

SUNRISE SYMPOSIA

Advances in Transplantation for the Diabetic, Uremic Transplant Candidate through Sequential Kidney and Pancreas or Islet Transplantation

Moderators: David Axelrod and James Markmann, MD, PhD, Massachusetts General Hospital, Boston, MA

7:00 am – 7:25 am  A Single Center Experience with Pancreas-After-Kidney Transplantation
Jonathan Fridell, MD
Indiana University School of Medicine
Indianapolis, IN

7:25 am – 7:50 am  Predictors of Outcomes for Pancreas-after-Kidney Transplants: Analyses of National SRTR Data
Dixon Kaufman, MD, PhD
Northwestern University School of Medicine
Chicago, IL

7:50 am – 8:15 am  Advances in Islet Transplantation for the Diabetic, Uremic Transplant Candidate
Andrew Posselt, MD, PhD
University of California, San Francisco
San Francisco, CA

B Lymphocytes in Transplant Rejection and Tolerance

Moderators: Stuart Knechtle, MD, PhD, Emory University School of Medicine, Atlanta, GA and Richard Pierson, III, MD, University of Maryland, Baltimore, MD

7:00 am – 7:25 am  B Cell Genomics and Proteomics in Transplantation
Minnie Sarwal, MD, PhD, MRCP
Stanford University School of Medicine
Stanford, CA

7:25 am – 7:50 am  B Cells and Plasma Cells in Rejected Cardiac Transplants
William Baldwin, MD, PhD
Cleveland Clinic Main Campus, Lerner Research Institute
Cleveland, OH
American Transplant Congress 2011 Preliminary Program

7:50 am – 8:15 am  Appearance of B Cell Biomarkers in Transplantation Tolerance
Kenneth Newell, MD, PhD
Emory University
Atlanta, GA

Beyond the SRTR Expected Outcomes: How Should We Determine the Adequacy of Solid Organ Transplant Programs’ Performance?—ARS (Barry Friedman)
Moderators: Kenneth Andreoni, MD, The Ohio State University, Columbus, OH and Bertram Kasiske

7:00 am – 7:15 am  How Does the Joint Commission Certify other Non-Transplant Boutique Programs?
Jean Range

7:15 am – 7:30 am  The Debate Concerning the Public Reporting of Cardiovascular Outcomes
Janis Orlowski, MD
Washington Hospital Center
Washington, DC

7:30 am – 7:50 am  Where Should We Go with Evaluation of Solid Organ Transplant Center Performance?
Chuck Mowll, FACHE
The Joint Commission
Washington, DC

7:50 am – 8:05 am  The Measure of Transplant Programs from the Private Payer View
Dennis Irwin, MD
OptumHealth
Minneapolis, MN

8:05 am – 8:15 am  Discussion

Donor-Derived Infections
Moderators: Shelly Morris, MD, University of Miami, School of Medicine, Miami Beach, FL and Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy

7:00 am – 7:25 am  Transplant-Associate Transmission of Infection and Malignancy: DTAC Report 2011
Emily Blumberg, MD
Hospital of the University of Pennsylvania  
Philadelphia, PA

7:25 am – 7:50 am  New Challenges: Chikungunya and Dengue?  
Paolo Grossi, MD, PhD  
University of Insubria  
Varese, Italy

7:50 am – 8:15 am  Prevention of Transmission of Tuberculosis and West Nile Virus: Consensus Recommendations  
Marian Michaels, MD, MPH  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA

The Emerging Field of Vascularized Composite Allotransplantation  
Moderators: Stefan Tullius, MD, PhD, Brigham and Women’s Hospital, Boston, MA and Linda Cendales, MD, Emory University School of Medicine, Atlanta, GA

7:00 am – 7:25 am  The History & Evolution of Vascularized Composite Allotransplantation  
Max Dubernard, MD  
University of Lyon  
France

7:25 am – 7:50 am  Current Clinical Immunosuppressive Protocols  
Stefan Schneeberger, MD  
Innsbruck Medical University/Johns Hopkins University  
Innsbruck, Austria

7:50 am – 8:15 am  Diagnosis of Rejection in VCA  
Rolf Barth, MD  
University of Maryland School of Medicine  
Baltimore, MD

Hepatitis C Infection after Liver Transplantation—ARS (Seth Karp)  
Moderators: Robert Fontana, MD, University of Michigan, Ann Arbor, MI and Robert Brown, Jr., MD, PhD, New York Presbyterian Hospital, New York, NY

7:00 am – 7:25 am  Natural History of Hepatitis C Infection after Liver Transplantation  
Roberto Firpi, MD, MS  
University of Florida College of Medicine  
Gainesville, FL
7:25 am – 7:50 am  Immunosuppression in Post-transplant Hepatitis C: Are There Superior Strategies?
*Michael Charlton, MD*
*Mayo Clinic*
*Rochester, MN*

7:50 am – 8:15 am  Antiviral Therapy for HCV in the Post-transplant Setting
*Frederic Gordon, MD*
*Lahey Clinic Medical Center*
*Burlington, MA*

**Long Term Follow Up of the Living Donor: Ethics vs. Finance—ARS (Debbie Hoch)**
*Moderators: Cathy Garvey and Dianne Lapointe-Rudow*

7:00 am – 7:25 am  Current Demographics of Living Donors in the United States
*Connie Davis*

7:25 am – 7:50 am  Living Donors without Insurance: Are We Responsible?
*Rebecca Hays, MSW, APSW*
*University of Wisconsin Hospital and Clinics*
*Madison, WI*

7:50 am – 8:15 am  Long Term Consequences of Living Donation
*Hassan Ibrahim, MD*
*University of Minnesota*
*Minneapolis, MN*

**Kidney Paired Donation: National Experience from US, Korea and Australia**
*Moderators: Edward Cole and Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD*

7:00 am – 7:25 am  Kidney Paired Donation in Australia
*Paolo Ferrari, MD*
*Fremantle Hospital*
*Perth, Australia*

7:25 am – 7:50 am  Kidney Paired Donation in South Korea
*Dae Jooong Kim, MD*
*Samsung Medical Center*
*Seoul, South Korea*

7:50 am – 8:15 am  Kidney Paired Donation in the United States
EARLY MORNING WORKSHOPS– TICKETED EVENT
7:00 am- 8:15 am

9. Diving Into the Deep End of the Liver Donor Pool
Moderators: John Renz, MD, PhD, University of Arizona, Tucson, AZ and Eric Schadde, MD, St. Louis University Hospital, St. Louis, MO

10. Interpretation of Donor Specific Antibody Testing and Crossmatch Techniques – SOLD OUT
Moderators: Peter Nickerson, MD, University of Manitoba, Winnipeg, Canada and M. Sue Leffell, PhD, Johns Hopkins School of Medicine, Baltimore, MD

11. Manuscript Writing Workshop
Moderators: Andrew Wells, PhD, University of Pennsylvania CHOP, Philadelphia, PA and Jonathan Maltzman, MD, PhD, University of Pennsylvania, Philadelphia, PA

12. New Onset Diabetes after Transplantation
Moderators: Harini Chakkera, MD, Mayo Clinic Hospital, Phoenix, AZ and Phuong-Thu Pham, MD, UCLA Medical Center, Charlottesville, CA

13. The Older Transplant Recipient
Moderators: Dianne McKay, MD, The Scripps Research Institute, La Jolla, CA and Patricia Adams, MD, Wake Forest University School of Medicine, Winston-Salem, NC

14. Transplant Infectious Diseases: Future Directions
Moderators: Atul Humar, MD, University of Alberta, Edmonton, Canda and Costi Sifri, MD, University of Virginia Health System, Charlottesville, VA

15. What is the Impact of IL-17 on Transplant Outcomes?
Moderators: William Burlingham, PhD, University of Wisconsin, Madison, WI and Nader Najafian, MD, Brigham & Women’s Hospital, Boston, MA
20. Role of ECMO in Thoracic Transplantation

*Moderators: Duane Davis, MD, Duke Medicine, Durham, NC and David Mason*

**BREAK**

8:15 am – 8:30 am

**JOINT PLENARY AND AWARDS**

8:30 am – 10:00 am

**STATE-OF-THE-ART ADDRESS**

10:00 am – 10:30 am  Rebuilding Autologous Organs: Cells, Scaffold, Organ

*Doris Taylor, PhD*

**COFFEE BREAK**

10:30 am – 11:00 am

**MIDDAY SYMPOSIA**

11:00 am – 12:30 pm

**ALDLT: An Update**

*Moderators: Elizabeth Pomfret, MD, PhD, FACS, Lahey Clinic Medical Center, Burlington, MA and Jean Emond, MD, Columbia University Medical Center, New York, NY*

11:00 am – 11:30 am  Donor Outcomes: Short and Long Term

*Paul Greig, MD  
Toronto General Hospital UHN  
Toronto, Canada*

11:30 am – 12:00 pm  ALDLT: Technical Lessons Learned from a High Volume Center

*Sung-Gyu Lee, MD  
Asan Medical Center of Ulsan University Medical School  
Seoul, Korea*

12:00 pm – 12:30 pm  ALDLT: Making Smaller Grafts Work

*Jean Botha, MB, BCh, FCS  
University of Nebraska Medical Center  
Omaha, NE*
**Lymphodepletion and Reconstitution of the T Cell Repertoire**

**Moderators:** Jonathan Bromberg, MD, PhD, University of Maryland, Baltimore, MD and Anna Valujskikh, PhD, The Cleveland Clinic Foundation, Cleveland, OH

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:00 am – 11:30 am | Homeostatic Reconstitution in Lymphopenic Environments  
Charles Surh, PhD  
The Scripps Research Institute  
La Jolla, CA |
| 11:30 am – 12:00 pm | Overcoming Homeostatic Proliferation of Memory T Cells in Allograft Recipients: What we have Learned in Rodent Models  
Laurence Turka, MD  
University of Pennsylvania Health System  
Philadelphia, PA |
| 12:00 pm – 12:30 pm | Reconstitution of the ATG-treated Transplant Patient  
Barbara Murphy, MD  
Mt. Sinai School of Medicine  
New York, NY |

**microRNAs: New Players in Gene Regulation, Tissue Injury and Rejection**

**Moderators:** Olivia Martinez, PhD, Stanford University School of Medicine, Stanford, CA and Anthony Jevnikar, MD, London Health Sciences Centre, University Hospital, London, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:00 am – 11:30 am | Transcriptional Control by microRNAs: New Drugable Targets for Transplantation  
Carl Novina, MD, PhD  
Dana-Farber Cancer Institute  
Boston, MA |
| 11:30 am – 12:00 pm | microRNAs as Biomarkers of Kidney Injury and T Cell Activation  
John Iacomini, PhD  
Brigham & Women’s Hospital  
Boston, MA |
| 12:00 pm – 12:30 pm | microRNAs in Human Renal Allograft Rejection  
Manikkam Suthanthiran, MD  
New York Presbyterian Hospital—Cornell  
New York, NY |
Update on “Big Science” in Transplant

Moderators: Mohamed Sayegh, MD, Brigham & Women’s Hospital, Boston, MA and Ali Naji, MD, University of Pennsylvania Hospital, Philadelphia, PA

11:00 am – 11:30 am  Collaborative Islet Transplant Consortium Results to Date
Camillo Ricordi, MD
University of Miami School of Medicine
Miami, FL

11:30 am – 12:00 pm  Clinical Trials in Organ Transplantation
Nancy Bridges, MD
NIH/NIAID
Bethesda, MD

12:00 pm – 12:30 pm  Immune Tolerance Network: Where We Stand with Tolerance Trials
Laurence Turka, MD
University of Pennsylvania Health System
Philadelphia, PA

Viral Hepatitis in Solid Organ Transplantation

Moderators: Norah Terrault, MD, MPH, University of California, San Francisco, San Francisco, CA and James Trotter, MD, University of Colorado HSC, Aurora, CO

11:00 am – 11:30 am  Prevention and Treatment of Recurrent Hepatitis C after Liver Transplantation
Marina Berenguer, MD
C/STA Genoveea Torres
Valencia, Spain

11:30 am – 12:00 pm  Preventing De Novo or Recurrent HBV after Liver Transplantation
John Lake, MD
University of Minnesota
Minneapolis, MN

12:00 pm – 12:30 pm  Viral Hepatitis in Non-Hepatic Organ Recipients: Donor and Recipient Considerations
Josh Levitsky, MD
Northwestern Memorial Hospital
Chicago, IL
Featured Symposium: Improving Long-Term Survival in Thoracic Transplantation: This session is co-sponsored by the International Society for Heart and Lung Transplantation (ISHLT)

Moderators: Bruce McManus, MD, PhD, University of British Columbia, Vancouver, Canada and Jason Christie, MD, University of Pennsylvania Medical Center, Philadelphia, PA

11:00 am – 11:30 am  Are We Better at Preventing Cardiac Allograft Vasculopathy (CAV)?
Howard Eisen, MD
Drexel University College of Medicine
Philadelphia, PA

11:30 am – 12:00 pm  How to Stop Chronic Heart and Lung Graft Injury from Antibody Mediated Rejection
Jon Kobashigawa, MD
Cedars Sinai Heart Institute
Beverly Hills, CA

12:00 pm – 12:30 pm  Managing Long-term Infection Risk in Thoracic Heart Transplantation
Robin Avery, MD
Cleveland Clinic Foundation
Cleveland, OH

Transplant Jeopardy
Host: Jay Fishman
Contestants: Michael Lucey, MD, University of Wisconsin Hospital & Clinic, Madison, WI, Dixon Kaufman, MD, Northwestern University Medical School, Chicago, IL and David Sutherland, MD, PhD, University of Minnesota Hospital, Minneapolis, MN

BREAK
12:30 pm – 12:45 pm

INDUSTRY LUNCHEON
12:45 pm – 2:00 pm
BREAK
2:00 pm – 2:15 pm

CONCURRENT ABSTRACT SESSIONS
2:15 pm – 3:45 pm

Concurrent Session 24: Antigen Presentation / Allorecognition / Dendritic Cells
Concurrent Session 25: CNI Toxicity/Transplant Outcomes
Concurrent Session 26: Donor and Recipient Outcomes
Concurrent Session 27: Economics, Public Policy
Concurrent Session 28: HLA Incompatible Kidney Transplantation
Concurrent Session 29: Immunoregulation in Transplantation
Concurrent Session 30: Liver Pediatrics
Concurrent Session 31: Living Liver Donors
Concurrent Session 32: Novel Immunosuppression in Transplantation I
Concurrent Session 33: Obesity and Metabolic Disease
Concurrent Session 34: PTLD/Malignancies
Concurrent Session 35: Transplantation Tolerance: Mechanistic Insights
Concurrent Session 36: Xenotransplantation

TRANSPLANTATION IN DEPTH
2:15 pm – 5:30 pm

Tolerance is an Active Immunological Process: Part I and Part II
Moderators: Jonathan Bromberg, MD, PhD, University of Maryland, Baltimore, MD and Maria-Luisa Alegre, MD, PhD, University of Chicago, Chicago, IL
Part I: Tolerance is an Active Immunological Process: Basic Individual Mechanisms of Tolerance

2:15 pm – 2:45 pm  Active Control of Central and Peripheral Deletional Tolerance
Mark Anderson, MD, PhD
University of California, San Francisco
San Francisco, CA

2:45 pm – 3:15 pm  Mechanisms of T Cell Anergy In Vitro and In Vivo
Thomas Gajewski, MD
University of Chicago
Chicago, IL

3:15 pm – 3:45 pm  Active Modulation of Tregs during Inflammation
Vijay Kuchroo

3:45 pm – 4:00 pm  Break

Part II: Tolerance is an Active Immunological Process: Mechanisms of Tolerance in Transplantation and Autoimmunity

4:00 pm – 4:30 pm  Cellular and Physical Requirements for Tolerance Induction in Transplantation: Role of MDSCs and Lymph Nodes
Jonathan Bromberg, MD, PhD
University of Maryland
Baltimore, MD

4:30 pm – 5:00 pm  Homeostatic Checkpoints Necessary for Induction and Maintenance of Tolerance
Laurence Turka, MD
University of Pennsylvania Health System
Philadelphia, PA

5:00 pm – 5:30 pm  Maintenance of Tolerance: Mechanisms That Can Break Transplantation Tolerance after It Has Been Stably Established
Anita Chong, PhD
University of Chicago
Chicago, IL

ALLIED HEALTH SYMPOSIUM

3:00 pm – 4:30 pm
Living with an Organ Transplant in 2011: Management of Cardiovascular and Oncologic Co-Morbidity
Moderators: Margaret Bia, MD, Yale University School of Medicine, Guilford, CT and Deborah Adey, MD, University of Vermont, Burlington, VT

3:00 pm – 3:30 pm  Treatment of Post Transplant Hypertension
Stephen Textor, MD
Mayo Clinic Foundation
Rochester, MN

3:30 pm- 4:00 pm  Management of Post Transplant Hyperlipidemia
Richard Spong, MD
University of Minnesota
Minneapolis, MN

4:00 pm- 4:30 pm  Skin Cancer: Risk Factor Assessment, Prevention and Treatment
Christina Mitchell, MD
University of Florida
Gainesville, FL
CONCURRENT ABSTRACT SESSIONS
4:00 pm- 5:30 pm

Concurrent Session 37: ABO Incompatible Kidney Transplantation
Concurrent Session 38: Bone Metabolism
Concurrent Session 39: Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies II
Concurrent Session 40: Host Response to Infection
Concurrent Session 41: Islet Cell and Cell Transplantation
Concurrent Session 42: Kidney Transplantation: Steroid-Free Immunosuppression
Concurrent Session 43: Molecular Pathways
Concurrent Session 44: Non-Organ Specific: Allocation
Concurrent Session 45: Novel Immunosuppression in Transplantation II
Concurrent Session 46: "Omics" in Transplantation
Concurrent Session 47: Out with the Old? Novel Immunosuppression in Cardiac Transplantation
Concurrent Session 48: Small Bowel: All Topics
Concurrent Session 49: Surgical and Utilization Issues

POSTER SESSION III
5:30 pm – 6:30 pm

AST BUSINESS MEETING
5:45 pm – 6:15 pm

ATC/ITNS DINNER– TICKETED EVENT
7:00 pm
Improving Transplant Outcomes: Incorporating Evidence into Transplant Nursing Practice
Moderator: Christine Shay
Speakers: Sandy Cupples, PhD, RN and Cynthia Russell, PhD, RN, ACNS-BC
Tuesday, May 3

SUNRISE SYMPOSIA
7:00 am – 8:15 am

The Critically Ill Lung Transplant Candidate: Clinical Management and Donor Selection—ARS (Seth Karp)

Moderators: David Mason, MD, Cleveland Clinic Foundation, Cleveland, OH and David Zaas, MD, MBA, Duke University, Rochester, NY

7:00 am – 7:25 am Extracorporeal Bridge to Lung Transplantation
Marc de Perrot, MD, MSc
University of Toronto
Toronto, Canada

7:25 am – 7:50 am Donor Selection for the Critically Ill Patient
Stuart Sweet, MD, PhD
Washington University
St. Louis, MO

7:50 am – 8:15 am When is it Time to Delist the Critically Ill Patient?
Sudish Murthy, MD, PhD
Cleveland Clinic
Cleveland, OH

Barriers to the Recovery and Placement of High Risk Organs—ARS (Chris Freise)

Moderators: Randall Sung, MD, University of Michigan Health System, Ann Arbor, MI and Herwig-Ulf Meier-Kreische, MD, University of Florida, Gainesville, FL

7:00 am – 7:25 am Current Utilization of High Risk Organs
Jesse Schold, PhD, M.Stat, M.Ed
Cleveland Clinic Foundation
Cleveland, OH

7:25 am – 7:50 am Use of High Risk Organs in the Current Environment: The Transplant Center Perspective
Chris Freise, MD
University of California, San Francisco
San Francisco, CA
The Role of the OPTN and Allocation Policy in Facilitating the Use of High Risk Organs
Kenneth Andreoni, MD
The Ohio State University
Columbus, OH

What Every Clinician Should Know About Designing Better Transplant Trials
Moderators: David Ikle, PhD, Rho Inc., Chapel Hill, NC and Donald Hricik, MD, University Hospitals Case Medical Center, Cleveland, OH

Clinical Trial Outcomes: Longitudinal vs. Cross-Sectional Endpoints
Ronald Helms

Sample Size Analyses in the Planning of Clinical Trials
Ralph O’Brien

Design Considerations in Solid Organ Transplant Trials
David Ilke, PhD
Rho Inc.
Chapel Hill, NC

Development of Small Molecules for Therapeutics
Moderators: Alessandro Alessandrini, PhD, Massachusetts General Hospital, Boston, MA and Jonathan Maltzman, MD, PhD, University of Pennsylvania, Philadelphia, PA

Small Molecules Engineered to Inhibit Cell Signaling Events
Craig Crews, MD
Yale University
New Haven, CT

Molecular Inhibitors of Complement Activation Attenuate Inflammation
Carl Atkinson

Small Molecule Inhibitors of Cytokine Receptors
Stanley Shaw, PhD
Massachusetts General Hospital
Boston, MA

Immunosuppressive Agents and Infectious Disease
Moderators: Emily Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA and Camille Kotton, MD, Massachusetts General Hospital,
Boston, MA

7:00 am – 7:25 am  Monitoring for Infection in Clinical Trials
Marian Michaels, MD, MPH
Children’s Hospital of Pittsburgh
Pittsburgh, PA

7:25 am – 7:50 am  Belatacept: PTLD and Other Infectious Risks?
Michael Green, MD, MPH
Children’s Hospital of Pittsburgh
Pittsburgh, PA

7:50 am – 8:15 am  Newer Biologics and Infectious Disease
Camille Kotton, MD
Massachusetts General Hospital
Boston, MA

Memory T Cell Responses and Induction of Tolerance
Moderators: Peter Heeger, MD, Mt. Sinai School of Medicine, New York, NY and Anna Valujskikh, PhD, The Cleveland Clinic, Cleveland, OH

7:00 am – 7:25 am  Heterologous Memory T Cell Responses and Tolerance
Mandy Ford

7:25 am – 7:50 am  Homeostatic Expansion of Memory T Cells and Tolerance
Faddi Lakkis, MD
University of Pittsburgh/Starzl Transplant Institute
Pittsburgh, PA

7:50 am – 8:15 am  Memory T Cell Responses and Tolerance in Primates
Gilles Benichou, MD, PhD
Massachusetts General Hospital
Boston, MA

The Multi-Disciplinary Approach to Hepatocellular Cancer—ARS (David Foley)
Moderators: Kevin Korenblat, MD, Washington University, St. Louis, MO and John Lake, MD, University of Minnesota, Minneapolis, MN

7:00 am – 7:25 am  Molecular Biology of HCC
Lewis Roberts, MBChB, PhD
Mayo Clinic
Rochester, MN
American Transplant Congress 2011 Preliminary Program

7:25 am – 7:50 am  Local-Regional Treatment of Hepatocellular Cancer
Julie Heimbach, MD
Mayo Clinic
Rochester, MN

7:50 am – 8:15 am  Milan and Beyond: Resection vs. Transplantation (Pros, Cons, and Actual Results)
Kenneth Washburn, MD
University of Texas HSC
San Antonio, TX

Renal Disease in Liver Transplantation—ARS (Seth Karp)
Moderators: Roy Bloom, MD, Hospital of the University of Pennsylvania, Philadelphia, PA and James Eason, MD, FACS, University of Tennessee—Methodist University Hospital, Memphis, TN

7:00 am – 7:25 am  Preserving Renal Function While on the Waiting List
Connie Davis, MD
University of Washington
Seattle, WA

7:25 am – 7:50 am  Indications for Combined Liver/Kidney Transplantation
James Eason, MD, FACS
University of Tennessee—Methodist University Hospital
Memphis, TN

7:50 am – 8:15 am  Post-transplant Management of Acute and Chronic Kidney Disease
Julie Thompson, MD
University of Minnesota
Minneapolis, MN

EARLY MORNING WORKSHOPS
7:00 am – 8:15 am

16. Grant Writing Workshop for Principal Investigators
Moderators: Jonathan Bromberg, MD, PhD, University of Maryland, Baltimore, MD and Robert Fairchild, PhD, Cleveland Clinic Foundation, Cleveland, OH

17. High Risk Living Donor— SOLD OUT
Moderators: Stephen Textor, MD, Mayo Clinic Foundation, Rochester, MN and Eric Gibney, MD, Piedmont Hospital, Atlanta, GA
18. Immune Privilege in Transplantation  
Moderators: William Burlingham, PhD, University of Wisconsin, Madison, WI and Peter Heeger, MD, Mt. Sinai School of Medicine, New York, NY

19. Molecular Reading of Transplant Biopsies  
Moderators: Banu Sis, MD, FRCPC, University of Alberta, Edmonton, Canada and Anthony Demetris, MD, UPMC—Montefiore, Pittsburgh, PA

21. The Virtual Crossmatch: Understanding its Role in Wait List Management—SOLD OUT  
Moderators: Howard Gebel, PhD, Emory University Hospital, Atlanta, GA and Kathryn Tinckam, MD, MMSc, FRCPC, University Health Network, Toronto, Canada

22. What Are the Barriers to Optimal Utilization and Outcomes for Kidney Transplantation from Small/Young Pediatric Donors?  
Moderators: Jorge Ortiz and Liise Kayler, MD, University of Florida, Gainesville, FL

BREAK  
8:15 am – 8:30 am

JOINT PLENARY AND AWARDS  
8:30 am – 10:00 am

STATE-OF-THE-ART ADDRESS  
10:00 am – 10:30 am

2099 - A Look Back at Tissue Engineering and Regenerative Medicine in the 21st Century  
Joseph P. Vacanti

BREAK  
10:30 am – 11:00 am

PRESIDENTIAL ADDRESSES  
11:00 am – 12:00 pm
AST AND ASTS AWARDS
12:00 pm – 12:30 pm

INDUSTRY LUNCHEON
12:45 pm – 2:00 pm

BREAK
2:00 pm – 2:15 pm

CONCURRENT ABSTRACT SESSIONS
2:15 pm – 3:45 pm

Concurrent Session 50: B Cell / Antibody
Concurrent Session 51: Disparities in Access to Transplantation
Concurrent Session 52: Glomerular Disease / PKD
Concurrent Session 53: Key Topics in Transplant ID
Concurrent Session 54: Kidney Immunosuppression: Induction Therapy I
Concurrent Session 55: Kidney: Pediatrics
Concurrent Session 56: Liver Complications: Surgical Considerations
Concurrent Session 57: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation I
Concurrent Session 58: Novel Aspects in T Regulatory Cell Biology
Concurrent Session 59: Selection Issues
Concurrent Session 60: Therapy of Antibody Mediated Rejection
Concurrent Session 61: Transplantation Monitoring-Beyond Regulation
Concurrent Session 62: Vascularized Composite Allografts - Clinical and Basic Science
FDA SYMPOSIUM
2:15 pm – 4:00 pm

FDA and Solid Organ Transplantation: Issues in the Practice of Medicine
Moderators: Patrick Archdeacon, MD, David Cohen and Robert Merion, MD, University of Michigan, Ann Arbor, MI

2:15 pm – 2:30 pm   Update on FDA Action in Organ Transplantation
Renata Albrecht, MD

2:30 pm – 2:45 pm   Beyond Maintenance Immunosuppression: Trial Designs for Indications other than Prevention of Acute Rejection in Solid Organ Transplantation
Ergun Velidedeoglu, MD

2:45 pm – 3:00 pm   Potential Pharmacodynamic and Pharmacogenomic Biomarkers in Solid Organ Transplantation: Summary of FDA Sponsored Workshop
Gerlie Gieser, PhD
FDA
Silver Spring, MD

3:00 pm – 3:15 pm   Approval of Generic Immunosuppression
Lawrence Yu, MD

3:15 pm – 3:30 pm   Approaches to Drug-Device Co-Development in Solid Organ Transplantation
Joette Meyer, PharmD

3:30 pm – 4:00 pm   Panel Discussion

ALLIED HEALTH SYMPOSIUM
3:00 pm – 4:30 pm

Psychosocial Impact on Postoperative Transplant Outcomes
Moderators: Cathy Garvey and Deborah Ann Hoch, DNP, Maine Medical Center, Portland, ME

3:00 pm – 3:30 pm   The Relevance of Alcohol Relapse in Orthotopic Liver Transplant
Andrea Dimartini, MD

3:30 pm – 4:00 pm   Managing Drug Seeking Behavior
Rebecca Hays, MSW, APSW
University of Wisconsin Hospital and Clinics
Madison, WI

4:00 pm – 4:30 pm Quality of Life Issues and Impact on Postoperative Outcomes
Frank Chessa, PhD
Bates College
Lewiston, ME

CONCURRENT ABSTRACT SESSIONS
4:00 pm – 5:30 pm

Concurrent Session 63: Antibodies / Serologic Assays and Clinical Implications
Concurrent Session 64: DGF / AKI
Concurrent Session 65: Disparities in Outcomes in Transplantation
Concurrent Session 66: Histocompatibility: B Cells and Plasma Cells
Concurrent Session 67: Immunosuppression Preclinical Studies
Concurrent Session 68: Islet: Clinical
Concurrent Session 69: Kidney Immunosuppression: Induction Therapy II
Concurrent Session 70: Kidney: Polyoma
Concurrent Session 71: Liver Complications: Issues that Relate to Surgical and Medical Management
Concurrent Session 72: Liver: Immunosuppression Acute / Chronic Rejection
Concurrent Session 73: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation II
Concurrent Session 74: Novel Mechanisms

POSTER SESSION IV
5:30 pm – 6:30 pm
CAREER DEVELOPMENT WORKSHOP
5:30 pm – 8:30 pm

Early Career Development Symposium
Moderators: Leonardo Riella, MD, Brigham & Women’s Hospital, Boston, MA and Michelle Josephson, MD, University of Chicago, Chicago, IL

5:30 pm – 5:40 pm Opening Remarks and Launching of Trainee and Junior Faculty CoP
Leonardo Riella, MD
Brigham & Women’s Hospital
Boston, MA

5:40 pm – 6:10 pm The Future of Clinical Research
Flavio Vincenti, MD
University of California, San Francisco
San Francisco, CA

6:10 pm – 6:40 pm Evolving Models of Basic Research and Translation to Clinical Practice
Peter Heeger, MD
Mt. Sinai School of Medicine
New York, NY

6:40 pm – 7:00 pm Job Negotiation
Barbara Murphy, MD,
Mt. Sinai School of Medicine
New York, NY

7:00 pm – 7:30 pm Panel Discussion on Career Opportunities in Academia and Beyond
Roslyn Mannon, MD
University of Alabama, Birmingham
Birmingham, AL

John Neylan, MD
Genzyme
Cambridge, MA

7:30 pm – 8:30 pm Networking Reception
ASTS BUSINESS MEETING
5:45 pm – 6:45 pm

INDUSTRY EVENT
7:00 pm

ATC NIGHT OUT
9:00 pm – 1:00 am
Wednesday, May 4

**SUNRISE SYMPOSIA**
7:00 am – 8:15 am

**Role of Mechanical Circulatory Support in Heart Transplantation**
*Moderators: Mariell Jessup, MD, Penn Institute for Immunology, Philadelphia, PA and Josef Stehlik*

7:00 am – 7:25 am  
VAD-induced Sensitization and Post-transplant Outcomes  
*Lori West, MD, DPhil*  
*University of Alberta*  
*Edmonton, Canada*

7:25 am – 7:50 am  
Can Survival with VAD Be As Good As Transplant?  
*Jeffrey Teuteberg, MD*  
*University of Pittsburgh*  
*Pittsburgh, PA*

7:50 am – 8:15 am  
Mechanical Support in Children: Present and Future  
*D. Morales, MD*  
*Texas Children’s Hospital*  
*Houston, TX*

**Assessing the Risk for Kidney Allograft Failure**
*Moderators: Michael Mengel, MD, University of Alberta, Edmonton, Canada and Fernando Cosio, MD, Mayo Clinic, Rochester, MN*

7:00 am- 7:25 am  
De Novo HLA-antibodies and the Risk for Allograft Failure  
*Michael Cecka, MD*  
*UCLA Immunogenetics Center*  
*Los Angeles, CA*

7:25 am – 7:50 am  
Histopathological Risk Factors in Kidney Allografts  
*Michael Mengel, MD*  
*University of Alberta*  
*Edmonton, Canada*

7:50 am – 8:15 am  
Molecular Risk Prediction from Kidney Allograft Biopsies  
*Gunilla Einecke, MD, PhD*  
*Medical School Hannover*
Hannover, Germany

Bone Disease in Kidney Transplant Patients: What Diagnostic and Therapeutic Approaches Should We Use?—ARS (Michelle Josephson)

Moderators: Margaret Bia, MD, Yale University School of Medicine, Guilford, CT and Michelle Josephson, MD, University of Chicago, Chicago, IL

7:00 am – 7:25 am  Diagnostic Approaches to Post-transplant Bone Disease
Stuart Sprague, DO
North Shore University Health System
Evanston, IL

7:25 am – 7:50 am  Treating Post-transplant Bone Loss: Are Bisphosphonates and Teriparitide Useful?
Maria Coco, MD
Montefiore Medical Center
Bronx, NY

7:50 am – 8:15 am  Regulating Mineral Disorders Post-transplant: Vitamin D, Calcium and Cinacalcet Use
Michael Germain, MD
Western New England Renal
Springfield, MA

Donor Management: Organ Donation and Critical Care

Moderators: Ginny McBride, MD, AMVAT Consulting, Grand Junction, CO and Ali Salim, MD, Cedars-Sinai Medical Center, Los Angeles, CA

7:00 am – 7:25 am  Current State of Organ Donation in the United States
John Roberts, MD
University of California, San Francisco
San Francisco, CA

7:25 am – 7:50 am  An Update from the SCCM/ACCP Organ Donor Task Force Consensus Guidelines
Sandra Lee Blosser, MD, FCCM
Penn State University
Mechanicsburg, PA

7:50 am – 8:15 am  Management of the Critically Ill Donor
Nader Habashi, MD
University of Maryland
Baltimore, MD
Small Bowel Transplantation: The Basics—ARS (Deb Sudan)

Moderators: Douglas Farmer, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA and George Mazariegos, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA

7:00 am – 7:25 am Small Bowel Transplantation: When and Why?
Simon Horslen, MD, ChB
Seattle Children’s Hospital
Seattle, WA

7:25 am – 7:50 am Small Bowel Transplantation: How and at What Risk?
Wendy Grant, MD
University of Nebraska Medical Center
Omaha, NE

7:50 am – 8:15 am Small Bowel Transplantation: Then What?
Thomas Fishbein

Stem Cell Mediated Therapy in Transplantation

Moderators: Robert Fairchild, PhD, Cleveland Clinic Foundation, Cleveland, OH and Anna Valujskikh

7:00 am – 7:25 am Overview of Stem cells and Role in the Inflammatory Response
Avinash Bhandoola

7:25 am – 7:50 am Regulatory Stem Cells and Allograft Tolerance
Lorenzo Piemonti, MD
San Raffaele Scientific Insitute
Milano, Italy

7:50 am – 8:15 am Mesenchymal Stem Cells as Immunomodulators
Jacques Galipeau, MD, FRCP
McGill Faculty of Medicine
Montreal, Canada

EARLY MORNING WORKSHOPS – TICKETED EVENT

7:00 am – 8:15 am

23. Challenges in Organ Donor Management

Moderators: Darren Malinoski, MD, FACS, Cedars-Sinai Medical Center, Los Angeles, CA and Michael Goldstein, MD, Mt. Sinai School of Medicine, New York, NY
24. Evolving Role of NK Cells in Solid Organ Transplantation
Moderators: Jonathan Bromberg, MD, PhD, University of Maryland, Baltimore, MD and Joren Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA

25. Molecular Expression Profiling to Assess Rejection Risk in Heart Transplantation
Moderators: Michael Pham, MD, Stanford University and Abdullah Kfoury, MD, Intermountain Medical Center, Murray, UT

26. Risks and Solutions in Transplantation and Policy Implications
Moderators: Daniela Ladner, MD, Northwestern Memorial Hospital, Chicago, IL and Donna Woods, PhD, Northwestern University, Aurora, CO

27. The Current Status of Liver Assist Devices
Moderators: Scott Nyberg, MD, PhD, Mayo Clinic, Rochester, MN and Jeffrey Fair, MD, Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA

28. Vascularized Composite Allotransplantation: Development of Donation Best Practices and Establishment of a VCA Program
Moderators: Jeffrey Orlowski, MS, Center for Donation and Transplant, Albany, NY and Linda Cendales, MD, Emory University School of Medicine

29. WHCOP Advisory Network
Moderators: Dianne McKay, MD, The Scripps Research Institute, Chicago, IL and Sheri Krams, PhD, Stanford University School of Medicine, Stanford, CA

Succeeding in a Basic Science Center
Kathryn Wood, DPhil
University of Oxford
United Kingdom

Succeeding in an Academic Medicine Career
Milagros Samaniego

Leading an Academic Department
Kimberly Brown
Henry Ford
Detroit, MI

Succeeding in Industry
American Transplant Congress 2011 Preliminary Program

Kathy Lake, PharmD
Roche Pharma
Dexter, MI

Succeeding in Allied Health
Linda Ohler, MSN, RN, CCTC
Georgetown University
Washington, DC

How to Balance Family and Career
Sheri Krams, PhD
Stanford University School of Medicine
Stanford, CA

Succeeding as a Woman in Transplant Surgery
Yolanda Becker, MD
University of Chicago
Chicago, IL

30. Auto Islet Transplantation
Moderators: Kenneth Brayman, MD, PhD, University of Virginia Health System, Charlottesville, VA and David Sutherland, MD, PhD, University of Minnesota Hospital, Minneapolis, MN

BREAK
8:15 am – 8:30 am

JOINT PLENARY AND AWARDS
8:30 am – 10:00 am

KEYNOTE ADDRESS
10:00 am – 10:30 am

The Not-So Distant Future of Organ Transplantation—Ethical Obstacles and Opportunities
Arthur Caplan

COFFEE BREAK
10:30 am – 10:45 am
CONCURRENT ABSTRACT SESSIONS
10:45 am – 12:15 pm

Concurrent Session 75: Antibodies

Concurrent Session 76: Antibody-Mediated Rejection: Histologic Findings and Clinical Implications

Concurrent Session 77: Basic Science: Innate Immunity; Chemokines, Cytokines

Concurrent Session 78: Complications following Liver Transplantation

Concurrent Session 79: Donor Topics

Concurrent Session 80: Extended Donor Issues

Concurrent Session 81: Late Allograft Failure: Immunity and Inflammation

Concurrent Session 82: Pregnancy and Other Posttransplant Issues

Concurrent Session 83: Stem Cell and BMT

WHAT’S HOT, WHAT’S NEW
12:15 pm – 1:15 pm

Moderators: Michael Abecassis and Robert Gaston, MD, University of Alabama at Birmingham, Birmingham, AL

12:15 pm – 12:45 pm  Clinical
Seth Karp, MD
Beth Israel Deaconess Medical Center
Boston, MA

12:45 pm – 1:15 pm  Basic
Roslyn Mannon, MD
University of Alabama, Birmingham
Birmingham, AL